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ABSTRACT 
Due to the importance of fluorescence assays in clinics, life science and genomic 
research, many nanostructures have been proposed to enhance the weak fluorescence 
signals from low abundance analytes. Among these structures, photonic crystal (PC) 
has attracted particular attentions because of its capability to produce high electric fields 
without quenching fluorescence emission. Properly designed PC surface can efficiently 
couple laser illumination to fluorescent dye molecules (enhanced excitation) and 
meanwhile effectively collects fluorescence emission (enhanced extraction).  
In this dissertation, photonic crystal enhanced fluorescence (PCEF) was used for 
disease biomarker dissertation. We applied PCEF to multiplexed microspot 
immunoassays for detection of allergen-specific antibodies. The PCEF system was able 
to detect low concentrations of Fel d1 specific IgE ~0.02 kU/L, which is 5-fold to 17-fold 
more sensitive than the commercially available FDA-approved analyzers.  
We also aimed to improve the current platform by incorporating a PC surface 
with a microfluidic chip in order to enable a rapid and automatic biomarker analysis at 
microliter sample consumption. We fabricated a plastic microfluidic device for holding 
the PC using a low-cost and flexible process and developed a leak-free automation 
system to introduce the correct sequence of fluids through the microfluidic device. The 
PCEF platform was successfully automated to enable more rapid, high sensitivity 
detection and a simplified output that will be readily usable by a clinician.  
Besides microarray immunoassays, the PCEF platform was also adapted to a 
molecular beacon assay for miRNA detection, where the PC surface was incorporated 
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with a submicron-height fluid channel. The use of the PCEF platform results in a 
reduction of the detection limits and an increase in the signal-to-noise ratio (SNR) with a 
small, inexpensive detection instrument.  
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CHAPTER 1: INTRODUCTION 
1.1 Chapter Introduction 
There is an urgent need for blood-based molecular tests to assist in the 
detection and diagnosis of diseases in a cost-effective manner at an early stage. 
Additionally, detection of molecular biomarkers in blood can classify diseases 
into distinct molecular subtypes and monitor their relapse and response to 
treatment. Increasingly, biomarker strategies are becoming critical to identify a 
specific patient subpopulation that is likely to respond to a new therapeutic agent. 
The improved understanding of the underlying molecular features of many 
challenging diseases and the availability of a multitude of recently developed 
technologies to interrogate the biomarkers in biological fluid have made it 
possible to develop clinically applicable and cost-effective tests for many 
diseases, even cancers. Overall, the paradigm shift toward personalized and 
individualized medicine relies heavily on the increased use of diagnostic 
biomarkers and classifiers to improve diagnosis, management and treatment. 
Fluorescence sensing is the most widely used detection technique in 
molecular diagnostics [1-3] and genomic/proteomic research [4-6], due to the 
wide availability of dyes that can be easily conjugated to broad classes of 
biomolecules and detected with high sensitivity. By labeling biomolecules with 
fluorescent molecules, researchers can obtain useful information such as spatial 
distribution of biomolecules in cells, abundance of biomolecules in a test sample 
or hybridization reaction between biomolecules, among a multitude of other 
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potential applications. The novel tool ensures that the practice of molecular 
biology becomes increasingly quantitative. 
There is a strong need to improve the performance of the dyes because of 
their importance in molecular biology. Researchers have made great efforts in 
the past decades to augment the performance of these molecules both in 
biological and non-biological contexts. Many novel nanostructures have been 
proposed to enhance the weak fluorescent signals from the low-concentration 
analyte [7-10], including metal-coated slides [11], plasmonic gratings [12, 13], 
two-dimentional (2D) photonic crystals (PCs) [14] and nanoantennas [15, 16]. By 
performing the assay protocol upon the surface of the nanostructures, sensitivity 
gains of over two orders of magnitude have been demonstrated. Among these 
structures, photonic crystals have attracted particular attention because of their 
capability to produce highly surface-bounded electric fields without quenching the 
fluorescence emission. 
Recently, one-dimensional (1D) PCs have been engineered by 
Cunningham’s group to enhance the signal from the common microarray dye 
Cyanine [17, 18]. The 1D PC utilizes high-quality factor resonances from a 
periodic dielectric surface structure to enhance the fluorescence output. Photonic 
crystal enhanced fluorescence (PCEF) allows the fluorophore to be excited by a 
small, compact, and inexpensive semiconductor laser instead of a high-power 
laser. Likewise, the greater fluorescence emission provided by PCEF can be 
readily detected with inexpensive imaging cameras that do not require costly 
liquid nitrogen cooling or electron multiplication. Using these advantages, we 
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have demonstrated 0.1 – 1.0 pg/ml detection of protein biomarkers in serum 
using an instrument we assembled at a retail cost of ~$10K [19]. Our current 
work involves applications of the PCEF system in the detection of plant 
expression, soluble protein, human autoantibody, and miRNA, with the goal to 
improve sensitivity and minimize the sample consumption. 
This chapter provides background on molecular diagnostics, fluorescence 
assays and the progress to date in the field of enhanced fluorescence including 
photonic crystal enhanced fluorescence (PCEF). The significance of molecular 
diagnostics, especially the detection of biomarkers in blood, is clearly stated. 
Then, two types of fluorescence assays that play important roles in biomarker 
detection are discussed. Special attention is given to enzyme-linked 
immunosorbent assay (ELISA) microarray and fluorescence resonant energy 
transfer (FRET) assay, as they are closely related to our current work. This is 
followed by a brief discussion on the basic mechanisms of fluorescence 
enhancement and the recent work in this field attributed to the progress of micro 
and nanotechnologies.  
1.2 Molecular Diagnostics 
Diagnostics tests inform a wide range of medical decision making, 
therefore they are an integral and critical part of our health care system. There 
are two primary areas of health care diagnostics: ‘‘in vivo’’ imaging or ‘‘in vitro’’ 
diagnostics (IVD). Imaging technologies include X-rays, ultrasonic waves, 
magnetic resonance, or radio-nuclear method that produce images of the body 
and its organs and other structures. IVDs are tests performed on a sample 
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taken from the body (blood, tissue, sputum, urine, etc.). One growing subset of 
IVDs is molecular diagnostics, which has captured particular attention in recent 
years because these types of tests bring deep insights to diagnosis and 
treatment. Molecular diagnostics is one of the most dynamic and transformative 
areas of diagnostics, leading to advances in research and treatment that are 
revolutionizing healthcare across a wide range of diseases and health 
conditions. 
‘‘Molecular diagnostics’’ refers to a class of diagnostic tests that assess a 
person’s health literally at a molecular level, as it detects and measures specific 
genetic sequences in deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or 
the proteins they express. Molecular diagnostics identifies gene, RNA, and 
protein variations that shed light on whether a specific person is predisposed to 
have a disease, whether they actually have a disease, or whether a certain 
treatment option is likely to be effective for a specific disease. Before molecular 
diagnostics, doctors made medication decisions based on the patients’ history 
and their symptoms. This traditional ‘‘evidence-based’’ diagnostics is heavily 
dependent on the doctors’ experiences and could delay the medical treatment 
since decisions can only be made after diseases are fully developed. Molecular 
diagnostics, however, is capable of detecting diseases at their early stage and 
even predicting their severity and patients’ survival rates, thus saving valuable 
time and resources for the patients. In addition, molecular diagnostics plays 
important roles in drug discover and finding the effective treatment for patients. 
With the help of molecular diagnostics, it is possible to realize ‘‘personalized 
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medicine’’ which allows clinicians to avoid treating every patient based on what 
he or she broadly has in common with other patients to treating them as 
individuals with optimized treatment for every individual patient. For example, 
by understanding underlying molecular mechanisms, a patient with a specific 
gene mutation in their cancer can be divided into a subgroup with a specific 
type of lung cancer and receive a specialized treatment. 
Of course, the ultimate power of personalized medicine is the ability to 
treat each individual patient with therapies tailored to the molecular profile of 
his/her individual disease (e.g., cancer). When specific proteins or genetic 
sequences have a known association with a specific health condition or disease, 
they are often referred to as ‘‘biomarkers’’ because they are markers of that 
condition or disease. Molecular diagnostics is a tool that is driving the 
continuing discovery of biomarkers at the research level, which in turn leads to 
treatments designed around these biomarkers. Then molecular diagnostics 
plays an additional critical role by ensuring that these new therapies are 
delivered to the right patient through more accurate diagnosis of the exact 
nature of their individual disease. This has led to the emerging field of 
companion diagnostics, in which a molecular diagnostic test is used to identify 
whether a specific therapy (a companion to the diagnostic) is likely to be 
effective for an individual patient.   
Molecular diagnostics examines and assesses functions of DNA, RNA, 
and proteins that were produced because diseases disrupt the function of cells. 
These biomarkers exist in patients’ tissues, fluids, tumors, or in the infectious 
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agents themselves that cause the disease. For example, when specific 
mutations, or sets of mutations, are known to be biomarkers associated with a 
disease or condition, molecular diagnostic tests can examine a patient’s genes 
to determine whether those mutations are present. These tests may look only 
for those certain gene variants, or map the entire sequence of a targeted 
portion of DNA to detect all mutations in the sequence. The test results, 
therefore, can assess a person’s risk of developing a disease, determine 
whether a person is a carrier of a hereditary condition, screen for diseases that 
are present but not yet symptomatic, or provide a diagnosis of existing 
symptoms. 
1.3 Biomarker Detection in Blood 
Blood has been regarded as a source of information on illness and 
health since ancient times. Biomarkers in blood have a great deal of promise for 
facilitating personalized medicine, including detection, diagnosis, prognosis, 
and monitoring of therapy. Although the broadest definition of a biomarker also 
includes the measurement of physiological and anatomical criteria, for 
molecular diagnostics the term refers to measuring the levels of biological 
molecules associated with the disease, such as specific proteins or genes. If 
these biomarkers are detected in the blood in abnormally high concentrations, it 
may suggest a diagnosis. 
A key unmet need for biomarker detection to achieve clinical relevance is 
improved sensitivity. Early diagnostic applications for cancer, for example, 
require detection of biomarkers that are produced by, or in response to a small 
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number of cells. The biomarker is diluted throughout the volume of blood within 
a person, so that when a sample of peripheral blood is drawn the biomarker 
concentration can be <1-10 pg/ml.  (For reference, 1 pg/ml of a typical cytokine 
such as IL-6 is equivalent to ~45 fM.  A 10 ml sample at this concentration 
contains 0.45 attomoles of IL-6.) In addition to high sensitivity, clinical 
diagnostic laboratories require high throughput automated platforms that can 
perform multiplexed biomarker analysis that can quantify small changes in 
concentration that can be performed rapidly at low cost/assay.  Moreover, it is 
widely recognized that these circulating biomarkers are highly variable across 
individuals, and that it will likely be necessary to utilize a panel of blood 
biomarkers to accurately detect or characterize a disease. Consensus is 
emerging that multiple, mutually exclusive biomarkers in an assay will lead to 
better clinical management of disease, compared to assessment of a single 
biomarker, and allow subtle differences in patient populations (gender, race, 
age) to be understood [20-22].  
 Current methodologies for multiplexed, sandwich ELISA analysis are the 
bead-based approaches (Luminex, $100K instrument capable of 500x 
multiplexing, and ~$3/assay for each target) and electrochemiluminescence 
technology (MesoScale Discovery – $190K for the Sector Imager 6000 
instrument and $1500 for a 24-well plate that images 100 spots/well).  However, 
these approaches typically use >50 ml of serum, require an expensive non-
automated detection instrument, provide limited multiplexing capability, and 
have lengthier assay protocols than microarrays.  While Luminex systems 
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deliver similar detection limits as conventional ELISA, (1-10 pg/ml for common 
cytokines), they require ~7 hour assay protocols to achieve them [23-26].  
Another promising technology for high sensitivity biomarker detection is the 
Simoa system offered by Quanterix [27], which uses a fluorescent reporter 
molecule attached to antibody-functionalized magnetic beads isolated in 50-fl 
reaction chambers to achieve non-multiplexed fM-scale detection limits with a 
more complex protocol than microspot ELISA. Likewise, the Erenna 
immunoassay technology offered by Singulex claims 1 fM detection limits using 
functionalized magnetic microparticles, fluorescent dye tags, and a custom 
format flow cytometer, but is not capable of multiplexed assays. All these 
systems utilize expensive purified antibodies and secondary antibodies to 
capture and label each target analyte. 
The goal of our research work is to develop a biomarker detection 
platform to enable rapid, high-sensitivity, multiplexed and automatic detection 
and a simplified output that can be readily usable by a clinician. Fluorescent 
assay, especially molecular beacon assay and sandwich antibody microarray, is 
chosen for biomarker detection as they have been reported to optimally use a 
small volume of sample to detect analytes at low concentrations that lack assay 
cross-reactivity and demonstrate the fastest binding kinetics. By enhancing 
fluorescence from the assay using a nanostructured surface PC, higher 
sensitivity can be achieved. The goal of this dissertation is to develop a more 
compact, inexpensive and practical instrument than current, alternative 
approaches.  While clinically relevant concentrations for many biomarkers are in 
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the range of 10-100 pg/ml [28], the ability to reduce limits of detection through 
the development of a more sensitive technology potentially results in even 
earlier disease diagnosis, while increasing the signal-to-noise ratio (SNR) for 
analyte concentrations in samples that are currently near the limits of existing 
approaches.  Significantly, amplification of fluorescence signals allows for 
detection of fluorescent emission that could not otherwise be performed without 
expensive high-power lasers and cooled electron-multiplied CCD cameras, thus 
yielding a low-cost detection instrument that uses an inexpensive 
semiconductor laser and an inexpensive sensor. The approach developed here 
may be broadly applied to a wide variety of multiplexed assays, including 
fluorescent microspot sandwich ELISA for soluble protein antigens or nucleic 
acid microarrays for detection of miRNA-based biomarkers [29-31].  
1.4 Fluorescence Assays 
Fluorescence is associated with the electron transition. An electron at the 
ground state can be excited to a higher energy state with absorbing a photon, 
and subsequently relaxed to a lower energy state with emitting a photon. 
Typically the emitted photon has less energy than the absorbed photon, which is 
observed as the Stokes shift. The energy difference between absorbed and 
emitted photons is accounted for by vibrational relaxation. Fluorescence assay 
typically involves fluorophore labeled biomolecules. It is a powerful scientific tool 
to resolve the spatial distribution of biomolecules in a cell or determine the 
abundance of biomolecules in a sample. Fluorescence assays can be either 
surface-based or liquid-based as illustrated in Figure 1.1. Surface-based 
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fluorescence assays are generally measured with a single endpoint scan, after all 
assay steps are completed and the assay surface is dry. They are typically 
utilized for multiplexed assays in an array format. Liquid-based fluorescence 
assays, in contrast, are performed in a “homogeneous” format, with all assay 
components in a liquid environment, not coupled to a surface. They are typically 
measured in the cuvette.  
1.4.1 ELISA Microarray 
The most widely used surface-based assays are the microspot-based 
sandwich immunoassays, or ELISA microarrays. ELISA microarrays permit the 
simultaneous measurement of many substances in a small sample volume, 
therefore providing an attractive alternative approach for quantifying multiple 
components in serum for clinical applications and detecting cancer biomarkers 
[22, 32-34]. The sandwich ELISA using secondary antibodies with fluorescent 
tags has demonstrated the ability to classify metastatic breast cancer based on a 
blood test with sensitivities in the sub-pg/ml range.  
As illustrated in Figure 1.2, the microarray ELISA chip is manufactured by 
printing an array of individual capture antibodies in micro-spots, where each 
antibody is printed multiple times to enable evaluation of experimental variability. 
After a “blocking” step inhibits subsequent nonspecific protein binding, the chip is 
exposed to a test sample, providing an opportunity for analyte molecules to bind 
with their corresponding capture antibodies. A mixture of all the biotin-linked 
detection antibodies is prepared and incubated with the chip, where they bind an 
unoccupied epitope of the targeted captured antigen. All ELISA reagents must be 
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rigorously tested to prove there is no assay cross reactivity. The final assay step 
is the introduction of fluorophore-labeled streptavidin that attaches only to the 
biotinylated detection antibodies.  
1.4.2 Molecular Beacon Assay 
One representative example of liquid-based fluorescence assays is 
fluorescence resonant energy transfer (FRET) assays. They are mainstays for 
disease diagnostics, pathogen detection, life science research, and toxin 
detection. They involve the energy transfer from an excited molecular 
chromophore (the “donor”) to another chromophore (the “acceptor”), in which the 
magnitude of the fluorescent output is determined by the concentration of a 
target analyte [35-37]. FRET requires the donor and acceptor to be separated 
from each other by 0.1 – 10 nm, and that the fluorescence emission spectrum of 
the donor overlaps with the fluorescence absorption spectrum of the acceptor. 
When two biomolecules are tagged with separate donor and acceptor 
fluorophores, and subsequently mixed together in solution, their binding 
interaction can be sensed by illuminating the sample with a laser within the 
absorption band of the donor, and by observing a decrease in donor emission, 
combined with an increase in acceptor emission. Likewise, when a single 
biomolecule is tagged with both donor and acceptor fluorophores, the 
dissociation of the biomolecule can be inferred through an increase in donor 
emission, combined with a decrease in acceptor emission. FRET interactions 
scale with the sixth power of the separation between donor and acceptor, and 
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thus represent an extremely sensitive “molecular ruler” for measuring 
biomolecular binding, protein folding, and DNA folding. 
While FRET is an important molecular biology research tool, it has also 
evolved into a powerful diagnostic technology through the use of DNA “molecular 
beacons”! [38, 39]. As demonstrated in Figure 1.3, molecular beacons (MB) 
contain a stem-loop hairpin probe that is flanked by two short self-complementary 
sequences. A fluorescent dye and a suitable quencher for that dye are attached 
at each terminal of the short sequences. The dye and the quencher are close to 
each other, resulting in quenching of the fluorophore in the stem-loop structure. If 
we add the target molecules that are complementary to the hairpin probe, 
hybridization between the molecular beacon and the target will occur, which 
opens the hairpin probe and allows the fluorophore to emit. Fluorescence from 
the dye would be observed. MB probes have been designed and validated for a 
wide range of diagnostic assays, including detection of PCR products, detection 
of sexually transmitted disease, viral load assays, and single nucleotide 
polymorphisms [40]. 
1.5 Enhanced Fluorescence 
Enhanced fluorescence is typically associated with optical resonances. 
The most popular optical resonance employed for fluorescence enhancement is 
the surface plasmon resonance observed in metal structures, but ring 
resonances and guided-mode resonances observed in dielectric structures have 
been used as well. Optical resonances used for enhanced fluorescence are 
associated with strong evanescent electric fields upon illumination at the 
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resonance wavelength. The amplitudes of evanescent electric fields are many 
times higher than that of the incident light illuminating the sample and decay 
exponentially as they move away from the surface of the nanostructure. The high 
amplitudes of the evanescent fields result in enhanced fluorescence for two 
reasons. Firstly, the increased local excitation photon density results in more 
excited electrons. As fluorescence is essentially a spontaneous emission 
process, the proportion of excited molecules in a fixed population of fluorophores 
is directly proportional to photon density. We call it ‘‘enhanced excitation’’ 
throughout the text. Secondly, the resonator not only can interact with the 
excitation but also can directly affect fluorophore emission. For example, the high 
photon density of the evanescent electric field will increase the probability of 
photon emission. The presence of an optical resonator provides a pathway for a 
fluorophore to transfer its photons more efficiently than would be possible in free 
space. This effect has been showed by Purcell as early as 1946. Fluorophore’s 
emission is also influenced by directional emission of the resonance. The emitted 
photons are concentrated at a certain direction which is determined by the 
structure dispersion. The concentrated photons further increase the emission 
intensity. We call it ‘enhanced extraction’ throughout the text.  
1.5.1 Metal Enhanced Fluorescence 
Metal nanostructures have long been studied due to their extraordinary 
ability to manipulate incident lights. The very first metal structure that was studied 
for enhanced fluorescence was a thin metal film atop of a dielectric substrate [41-
43]. The surface of metal can support surface plasmons, the collective oscillation 
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of electrons that propagates along the surface. The surface plasmons in thin 
metal films can be resonantly excited by photons whose wave vector component 
parallel to the interface matches that of the surface wave, using a prism or 
grating coupler. At a resonant condition, the evanescent fields of the surface 
plasmons can interact with the flurophores. Fluorescence enhancement of ~3-7 
folds has be reported using gold or silver thin films [41]. 
While the first demonstration of the enhanced fluorescence relies on the 
flat metal surface, recent research efforts, however, are mostly focused on metal 
nanoparticles with localized surface plasmon resonance (LSPR), possibly 
because of the higher magnitude of enhancement and ease of using the 
instrument. Localized surface plasmons (LSP) are electron density oscilations 
confined to metallic nanoparticles and nanostructures. LSPR occurs when the 
LSP is excited at the resonant incident wavelength. LSPR is typically associated 
with strong light scattering, with the appearance of intense surface plasmon 
absorption bands and an enhancement of the local electromagnetic fields. 
Various metal nanostructures have been demonstrated to enhance fluorescence 
output. For example, enhancements of silver nanoprisms were reported when the 
wavelengths of LSPR of the particles overlapped excitation and emission 
wavelengths of various dyes [44]. Significant enhancement (greater than 300x) of 
cyanine dyes in the presence of silver nanoparticles on silicon substrates has 
been demonstrated [45].   
The field of surface-based metal enhanced fluorescence is hindered by 
several key limitations. First, enhancement factors are strongly influenced by the 
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distance between the radiating dipole and the metallic surface or particle. On the 
one hand, the fluorophore must be placed close to the surface because of the 
exponential decay of the electric field. On the other hand, the fluorophores can 
not be too close to the surface since the quenching effect dominates when they 
are in proximity. Therefore, distance of tens of nanometers from the metallic 
surface must be achieved to obtain a maximum enhancement. Furthermore, 
metals are lossy and cannot support very high-quality factor resonant modes. 
The inability to store a large amount of energy places an upper limit on the 
enhancement that can be achieved through plasmon assisted fluorescence 
excitation. In order to overcome these limits, dielectric nanostructures have been 
proposed for enhancing the fluorescence. 
1.5.2 Dielectric Enhanced Fluorescence 
Dielectric-based devices have also been used in an attempt to improve 
the sensitivity of fluorescence detection. The first demonstration of the dielectric-
based enhanced fluorescence is based on total internal reflection fluorescence 
(TIRF) [46]. It is a well-established technique in which light is coupled into a 
waveguide where it evanescently excites fluorophores on the device surface. The 
light is coupled into the waveguide with either a grating, a prism, or a high 
numerical aperture objective. By exciting only the fluorophores on the surface 
using evanescent coupling, background fluorescence can be minimized. The 
inherent spatial discrimination can yield dramatic improvements in signal-to-noise 
of the collected fluorescence. 
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Photonic crystal (PC), a corrugated waveguide structure with a periodic 
change of the refractive index, is an alternative substrate for enhancing 
fluorescence. The PC slab also demonstrates “evanescent resonance” as TIRF 
but could provide even higher enhancement of fluorescence compared to that of 
TIRF, because of the stronger evanescent electric field. The PC slab has a 
period that is smaller than the wavelength, resulting in the evanescence nature of 
the non-zero-order mode. A resonance in this structure is excited when these 
evanescent modes are re-radiated in-phase with the reflected zeroth-order wave 
and out-of-phase with the transmitted zeroth-order wave. Excitation of the 
resonances must be a certain combination of the incident wavelength and angle, 
which are usually obtained from the PC dispersive curves. These resonances are 
capable of enhancing fluorescence in a similar fashion to surface plasmon 
resonance, taking advantage enhanced excitation and enhanced extraction. The 
study of PC slabs by Budach and colleagues in 2003 demonstrated over 100x 
fluorescence enhancement for certain signals on a cDNA microarray on the PC 
slabs [47].  
Recently, PCs have been engineered by our group to enhance the signal 
from the common microarray dye Cyanine-5 (Cy5) by more than three orders of 
magnitude [19] when scanned by a system that is optimized for coupling light 
to/from the PC. We have successfully demonstrated the detection for a panel of 
breast cancer biomarkers using these PC slabs, achieving a lower detection limit 
compared to that on glass slides [8], [18],  [48], [49]. The resulting capability will 
address the needs of clinical diagnostics laboratories that currently lack the 
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capacity to easily measure the concentrations of large panels of biomarkers in 
blood for purposes of early diagnosis/screening, therapy selection, and routine 
treatment follow-up.  As a greater number of autoantibody biomarkers are 
identified and validated for viral infection, cancer, asthma, and autoimmune 
diseases, such a platform will have broad utility.   
1.6 Conclusion 
This chapter introduces the concept of Photonic Crystal Enhanced 
Fluorescence (PCEF) and how it can be applied to solve the current problems 
in biomarker detection. Throughout this thesis, the field enhancement property 
of the 1-D PC is applied to enhance the signal intensity emitted from 
fluorophores that are tagged to different biomarkers. Chapter 2 will detail how 
the PCEF technology works and various approaches to advance this 
technology. 
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1.7 Figures 
 
 
Figure 1.1. Applications and classifications of the fluorescence assays. There are mainly 
two types of fluorescence assays: the surface-based one and the liquid-based one.!
Surface-based fluorescence assays are typically utilized for multiplexed assays in an 
array format where the dye molecules are bounded to the surface. Liquid-based 
fluorescence assays, in contrast, are performed in a “homogeneous” format, with all 
assay components in a liquid environment, not coupled to a surface.  
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Figure 1.2. Schematic diagram of the ELISA micro-immunoassay. First, ELISA 
microarray is produced by printing an array of individual capture antibodies in micro-
spots. After a “blocking” step inhibits subsequent nonspecific protein binding, the chip is 
exposed to a test sample, providing opportunity for analyte molecules to bind with their 
corresponding capture antibodies. A mixture of all the biotin-linked detection antibodies 
is prepared and incubated with the chip, where they bind an unoccupied epitope of the 
targeted captured antigen. The final assay step is the introduction of fluorophore-labeled 
streptavidin that attaches only to the biotinylated detection antibodies. Reprinted from 
http://www.hoelzel-biotech.com. 
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Figure 1.3. Schematic diagram of the molecular beacon assay. Molecular beacons (MB) 
contain a stem-loop hairpin probe that is flanked by two short self-complementary 
sequences. A fluorescent dye and a suitable quencher for that dye are attached at each 
terminal of the short sequences. The dye and the quencher are close to each other, 
resulting in quenching of the fluorophore in the stem-loop structure (1). If we add the 
target molecules that are complementary to the hairpin probe, hybridization between the 
molecular beacon and the target will occur, which opens the hairpin probe and allows 
the fluorophore to emit (2). Fluorescence from the dye would be observed. Reprinted 
from http://www.sigmaaldrich.com. 
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CHAPTER 2 PHOTONIC CRYSTAL ENHANCED FLUORESCENCE  
2.1 Chapter Introduction 
The Photonic Crystal Enhanced Fluorescence (PCEF) provides a low-
cost, high sensitivity and multiplexed detection platform for biomarker research 
and disease diagnostics.  A wide variety of PC structures have been studied and 
fabricated for an enormous range of applications since the periodic nanostructure 
was first proposed to enhance fluorescence [50]. In this research work, the PCs 
designed to enhance fluorescence are comprised of a periodically modulated low 
refractive index dielectric surface structure coated with a high refractive index 
dielectric thin film.  The PC surfaces are engineered to interact strongly with any 
optical wavelengths of interest through selection of their materials and the 
parameters of their geometry [51, 52]. It takes advantage of PC resonances 
associated with two phenomena: ‘‘enhanced excitation’’ and ‘‘enhanced 
extraction’’. The simultaneous occurrences of both enhancement mechanisms 
has been shown to boost the emission from dye molecules by greater than three 
orders of magnitude [17]. 
A complete PCEF system is comprised of a PC surface and detection 
instruments. The design of the PC is critical to achieve large fluorescence 
enhancement. To confirm the optical properties of the fabricated devices, we 
build an optical system to measure the reflection spectrum of the PC. As for the 
fluorescence detection, our custom detection instrument can effectively couple 
PC and measure fluorescence. In this chapter, various aspects of PCEF platform 
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are discussed. The effects of enhanced excitation and enhanced extraction will 
be explained first. Following that, a standard manufacturing process for 
integrated circuit that is implemented to fabricate PCs will be described. Then, 
two fluorescence detection instruments will be discussed including a confocal 
laser scanner and a laser line scanner. Applications discussed throughout this 
thesis are based on the exact same PC device and detection instruments as 
described in this section. Finally presented is a brief review of the previous work 
where PCEF have been utilized to improve the sensitivity of detection of a 
biological assay. 
2.2 Principle of PCEF 
The PC is designed to enhance the fluorescent intensity though the 
enhanced excitation and enhanced extraction mechanisms. In order to vividly 
show PCEF, Figure 2.1 is provided to demonstrate the effect of enhanced 
electromagnetic field intensity on the emission intensity of a surface-bound 
fluorophore (quantum dots, QDs 405). Quantum dots were dispersed on the PC 
surface (right) and the un-patterned surface (left) surrounding the PC (acting as 
the control for comparison) as marked by the circles. The quantum dot emission 
intensity image on the top (Figure 2.1(a)) represents the condition when the PC 
is resonant (resonant wavelength l = 405 nm at q = 11.2°) with respect to the 
incident laser beam (l = 405 nm), showing an enhancement factor of over 108 
times with respect to the control. This enhancement is the result of both 
enhanced excitation and enhanced extraction. Even if PC is not resonant, some 
enhancement still exists due to the effect ‘‘enhanced extraction’’. The image on 
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the bottom (Figure 2.1(b)) is the emission intensity image when the PC is not 
resonant with the incident laser (q = 0°), i.e. without any pockets of strong 
localized electromagnetic fields. For this case the PC shows enhancement of 
13 times with respect to the control. Both enhanced excitation and enhanced 
extraction (the off-resonant enhancement) will be explained in the following 
section. 
2.2.1 Enhanced Excitation 
The increase in the evanescent electric field intensity of the excitation is 
called ‘‘enhanced excitation’’. The enhanced excitation can be achieved by 
illuminating the PC at a specific incident angle for a given laser illumination 
wavelength [53]. At the resonance coupling condition of the PC, the enhanced 
electric fields are confined to the surface of the device and extend into the 
adjacent media with exponentially decaying intensity, and thus only surface-
bound fluorophores will be exposed to enhanced energy from the laser. In 
addition, these optical resonances can be engineered to have a very high 
electromagnetic field density on the surface of a PC during their finite lifetime. 
The magnitude of this electromagnetic density localized within the PC is directly 
proportional to the quality factor of the resonance or its lifetime, which in turn is 
controlled by adjusting the device parameters. The intensity of emission from 
the fluorophores can be greatly enhanced by placing them in the proximity of 
the PC surface which has its resonant wavelength overlapping the absorption 
spectrum of the fluorescent species due to an enhanced absorption rate. Since 
the resonant response of the structure is different depending on the polarization 
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of the incidence, with Transverse Magnetic (TM) resonances being narrower in 
linewidth, implying a higher quality factor for the same device structure, TM 
resonances have higher electromagnetic field density on their surfaces and are 
preferred to Transverse Electric (TE) resonances for the purposes of enhanced 
excitation.  
2.2.2 Enhanced Extraction 
Due to the resonant effect, the emission from a fluorophore near a PC 
surface can couple to one of the resonant modes of the PC and then emerge 
out in an angle-dependent direction. This provides us with a powerful 
mechanism where the emission can be concentrated within specific directions 
and therefore detected with much higher sensitivity.  Such a scheme is 
particularly useful in improving the detection efficiency of instruments and can 
further help in reducing the detection limits of the fluorescent species. In most 
fluorescence detection instruments the detection optics are kept directly above 
the emitting species. When fluorescent species bound to the PC surface are 
imaged with such instruments, the PC is engineered so as to direct the coupled 
radiation normally toward the detection optics.  This enables the majority of the 
emitted radiation to be detected efficiently, unlike the radiation emitted by a 
fluorophore on the glass substrate with its emission almost uniform in all 
directions. Experiments have been performed to verify this process and, 
understand its role, in fluorescence enhancement for PCs possessing different 
symmetries [54]. It has been shown that for a narrow spectral and angular 
detection instrument, a PC with increased symmetry leads to greater 
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enhancement of emitted radiation in the normal direction. This has been 
attributed to increase in the number of diffraction planes that can interact with 
the omnidirectional radiation. 
The effects of ‘‘enhanced excitation’’ and ‘‘enhanced extraction’’ act 
independent of each other. Hence when they act together, their effects get 
compounded. These two effects can be independently optimized to design a PC 
that provides very large fluorescence enhancement factors. With the combined 
effect of the two, enhancement factors as large as 7500 have been 
demonstrated [17], making PCs a very desirable platform for a wide array of 
fluorescent biological sensing applications. 
2.3 PC Structure Design and Fabrication 
The PC is comprised of a periodic surface structure fabricated in a low 
refractive index (RI) silicon dioxide (SiO2) layer on a silicon substrate. The grating 
structure is coated with a high RI titanium dioxide (TiO2) thin film. The schematic 
diagram of the PC is shown in Figure 2.1(a). Simulation results dictated the use 
of a structure with a period of 360 nm, a duty cycle of 36%, a grating depth of 40 
nm, and a TiO2 thickness of 120 nm. 
A commercially available simulation tool for rigorous coupled wave 
analysis (DIFFRACTMOD, RSoft) was used to aid in the optimal design of a 
PCEF device. The end goal of the design is to achieve high enhancement and 
overlap the resonant peak of PC with the excitation peak of the fluorophore. Two 
factors mainly determine the resonant peak location including the period of the 
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grating and the thickness t of the TiO2 layer. Because of the phase match 
condition, the resonant wavelength λ must satisfy: λ = !!""Λ. Here !!""  is the 
effective index of the resonant mode at the resonant wavelength of λ for a PC 
with grating period Λ, which is affected by thickness t. The resonant peak location 
is far more sensitive to the change of the period Λ than thickness t. In the 
simulation, the period Λ was first determined to overlap with the emission peak of 
Cy5 while thickness t was slightly modified to fine tune the resonant peak. The 
enhancement is mainly determined by grating depth d. The grating in a PC is a 
diffractive element that couples the light into and out of the PC and thus is a 
source of the diffraction loss in the PC. The diffraction loss is directly related to its 
diffraction ‘‘strength’’ which is essentially related to its depth d. As the depth of 
grating decreases, the linewidth of its resonance also decreases thus increasing 
the Q-factor of the structure and the enhancement provided by the grating. A 
linewidth of 0.02 degree is achieved at the grating depth of 40 nm. Given that the 
detection instrument has the angle tolerance of 0.02 degree, we set the grating 
depth to be d = 40 nm. 
Advantages of using silicon as the substrate material of PC include its 
relatively low autofluorescence and its wide use in industrial manufacture. 
Previously, we fabricated plastic PC by nano-replica molding and demonstrated 
enhancements of SNR ~6.6 folds for detection of a panel of cancer biomarkers in 
a protein microarray format [8]. However, the plastic substrate with high 
autofluorescence increases background and limit the fluorescence detection. 
Then we switched to a quartz substrate [18, 55]  fabricated by a nano-imprint 
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lithography process. Although quartz substrate has extremely low 
autofluorescence thus showed a 330X SNR improvement for the detection of 
spotted Alexa-647 labeled polypeptide on PC, the nanoimprint approach is 
complicated, slow and unstable. That is why we finally fabricated these PC 
devices over the area of 8’’ diameter silicon wafers using lithography. A thermal 
oxide (thickness of 800 nm) was grown on each Si wafer and a deep UV 
photolithography process (193 nm, ArF-line) was used to create the grating 
pattern in the oxide layer. SEM image of the PC surface is presented in Figure 
2.2(b)(c). The device was then coated with TiO2 and diced into 1.0 x 0.5 inch2 
pieces. Photo of the diced piece is presented in Figure 2.2(d). 
The effectiveness of the light coupling into PC will determine the 
fluorescence enhancement. The process of determining the coupling condition of 
a PC involves the measurement of the wavelength spectra associated with the 
PC. It was experimentally determined by illuminating the PC by a collimated 
white light source, while the reflected light was detected by a spectrometer 
(Ocean Optics Inc.). The device was mounted on a rotational holder, and the 
reflection spectra at different incident angles were recorded utilizing a 
commercial software package (Spectra suite, Ocean Optics Inc.).  The spectrum 
with the resonant peak at λ = 637 nm indicates the condition where the laser can 
be efficiently coupled into the PC structure. The incident angle corresponding to 
this spectrum is recorded as the excitation angle to obtain maximum 
fluorescence enhancement.   
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2.4 Detection Instruments 
2.4.1 Confocal Laser Scanner 
A confocal microarray laser scanner (LS Reloaded, Tecan Inc.) was the 
first detection instrument used to study PC enhanced fluorescence. The 
schematic of the scanner is shown in Figure 2.3. This system is equipped with a 
He-Ne laser and a solid-state Nd-YAG laser as the excitation sources and a 
photomultiplier tube (PMT) to detect the emitted fluorescence signal.  The angle 
of incidence of the lasers can be tuned from 0° to 25°. In order to form an image, 
the substrate is scanned and the fluorescence signal intensity for each pixel is 
acquired. The instrument uses a lens to focus the laser beam onto the sample 
and collects the fluorescence signal resulting from this excitation. Due to the 
focusing effect, the laser beam has a beam divergence ~ 2.5°. Since the beam is 
not collimated, a substantial portion of the excitation energy does not get coupled 
into the resonant mode of the PC, thus compromising the enhancement 
performance of the PC.  
2.4.2 Laser Line Scanner 
A custom detection instrument was built to optimize coupling of laser 
illumination to the PC surface.  As described in previously published reports [56],  
the excitation laser is collimated in the plane perpendicular to the grating lines, 
but focused in the plane parallel to the grating (Figure 2.4). According to the 
simulation model, we need collimated light in order to most efficiently couple with 
the PC resonant mode, but the light need only be collimated with respect to a 
single axis.  Along the orthogonal axis, light can be focused without 
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compromising coupling efficiency to the PC, and thus focus along one axis is 
used to achieve high illumination intensity. The dispersive curves of PC in Figure 
2.5 prove that the coupling efficiency is only related to incident angle along one 
axis.  
The system is designed for optimal interaction with the PC for both 
enhanced excitation and enhanced extraction, using design principles discussed, 
modeled, and demonstrated in [19].  The focal point of the cylindrical lens is 
located at the back focal plane of the objective, resulting in a line of illumination 
in the PC that is collimated along the angle perpendicular to the PC grating lines, 
but focused in the orthogonal direction.  Linear translation of the cylindrical lens 
results in adjustment of the incident angle to achieve ‘‘on resonance’’ 
illumination.  A semiconductor laser diode (AlGaAs, 70 mW, λ = 637 nm) is 
expanded to a diameter of 1 mm, and focused to an 8 µm wide line onto the PC 
surface by a cylindrical lens. A mirror coupled to a computer-controlled linear 
translation stage enables adjustment of the incident angle from 0-20 degrees 
with 0.01 degree minimum increments.  The grating lines of the PC are oriented 
perpendicular to the scan line, allowing the laser (polarized output perpendicular 
to the grating) designed to excite the TM mode of the PC.   
2.5 PCEF for Multiplexed Protein Biomarker Detection 
With the use of PCEF and the customized detection platform, we have 
successfully detected a panel of >20 breast cancer biomarkers in a protein 
microarray format [57, 58]. Our results show that the resonant excitation effect 
increases the signal-to-noise ratio by 3.8-fold to 6.6-fold, resulting in a decrease 
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in detection limits of 6-89%, with the exact enhancement dependent upon the 
antibody-antigen interaction. Due to the enhancement provided by photonic 
crystal antibody microarrays, we detected common cancer biomarkers in the <2 
pg/mL concentration range within a mixed sample. 
Capture antibodies were first printed on the slide; replicate arrays are 
printed to assess the experimental variability in each slide. Following this, the 
slide was blocked to limit the non-specific binding of analytes in subsequent 
steps. The slide was then incubated with a test sample consisting of a mixture of 
biomarkers. Next, the slide was washed to remove all unbound biomarkers and 
then incubated with a mixture of biotinylated secondary detection antibodies. 
Finally, the secondary detection antibodies were labeled by incubation with 
streptavidin-Cy5 (Figure 2.6). We generated a standard curve for all the 
biomarkers by assaying a concentration series that covers a 10000-fold range of 
protein concentrations.  
The PC enhancement of fluorescence was determined by comparing the 
fluorescence output when the PC is illuminated with the excitation laser at an 
incident angle matched to the PC resonant angle (“on resonance”) to that when 
the illumination angle is not at the PC resonance (“off resonance”). The array 
exposed to the second-highest concentration in the dilution series were used to 
determine the enhancement factor. Their fluorescence images at on-resonance 
condition and off-resonant condition were collected and their fluorescence 
intensities were quantified by ImageJ. The fluorescence signal intensity was 
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enhanced by a factor of 11-fold to 20-fold by illuminating the PC at its resonant 
condition (Figure 2.7).  
Any fluorescence within the evanescent field region can be enhanced by 
PC, whether the source of the fluorescence is a Cy5 molecule bounded to the 
analytes, a Cy5 molecule captured by surfaces outside spots region, or 
autofluorescence from either the cover material or chemical functionalization 
layer. In fact, the background intensity is 4 to 5 times higher when the PC is on-
resonance compared to that at the off-resonance condition. However, we still 
observed an increase in SNR by 3.8-folds to 6.6-folds for the assays due to the 
fact that the magnitude of the PC enhancement within the capture spots region is 
greater than that in the regions between the spots. It is important to confirm 
enhancements in SNR for detecting antigens at low concentrations as this 
indicates an improvement in detection limit. For example, two antigens EGFR 
and uPAR were detected at concentrations as low as 3.6 and 7.1 ng/mL with PC 
on-resonance (SNR > 8), while the spot signals for EGFR and uPAR at these 
same concentrations were noise-limited (SNR < 3) and could not be 
differentiated from the local background fluorescence at off-resonance condition. 
Improved detection sensitivity of such antigens is beneficial to the early diagnosis 
of cancers, because cancer biomarkers in general are present at very low 
concentrations in serum. Standard curves were generated with the use of the 
signal intensities from each dilution in the concentration series. A representative 
standard curves for TNFa when the PC is on-resonance and off-resonance is 
presented in Figure 2.8. We found that when on-resonance, the PC 
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demonstrated better precision as indicated by the steeper slope in the linear 
region of the standard curves, and ~10-fold reduced limit of detection. 
2.6 Conclusion 
Our work is focused on applications of PCEF, for both surface-based 
fluorescent assays and homogeneous fluorescent assays. Following the work of 
the detection of soluble protein in human by applying PCEF to protein 
microarray, our research efforts are devoted to the detection of autoantibodies in 
human serum. Autoantibodies detection attracts increasing attentions due to their 
importance in infected diseases, allergy and cardiovascular diseases. Chapter 3 
shows that it is feasible to detect allergy-specific antibodies in human at low 
concentrations using the PCEF array system. In order to transfer the PCEF 
technology from a laboratory setting to a clinical tool or even a point-of-care 
(POC) device, our next improvement of the system is focused on assay 
automation that requires integration of the PC surface and microfluidic devices. 
In Chapter 4, we successfully demonstrate a platform that! integrates photonic 
crystal enhanced fluorescence (PCEF) detection of a surface-based microspot 
fluorescent assay with a microfluidic cartridge to achieve simultaneous goals of 
high analytic sensitivity (single digit pg/mL), high selectivity, low sample volume, 
and assay automation. On the other side, PCEF can also be used for 
homogeneous assay. Combined with the sub-micron-height channel, the PC 
surface successfully enhanced the fluorescence output from a molecular beacon 
assay. The sensitive detection of miRNA was realized on the PCEF platform and 
the results are summarized in Chapter 5.   
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2.7 Figures 
!
Figure 2.1 Fluorescence (pseudocolor) scan images of the PC with quantum-dots 
dispensed on the surface. The circular regions represent the area where the quantum 
dots are located. (a) Fluorescence from the PC surface was enhanced by 108 times 
compared to that on glass, when the PC is resonant with respect to the incident beam (q 
= 11.2°). This enhancement effect is the combination of enhanced excitation and 
enhanced extraction. (b) Scan taken when the PC is not resonant with the incident beam 
(q = 0°), showing an enhancement factor of over 13 times. This enhancement effect only 
includes enhanced extraction effect. (Reprinted from [53].) 
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Figure 2.2. (a) Schematic of the silicon PC device design. (b) Cross-sectional view of 
grating pattern in SiO2 layer before TiO2 coating. The grating line width and grating depth 
were measured to be 131 nm and 37.7 nm, respectively. (c) Top view of PC after TiO2 
coating. The grating period was measured to be 366 nm. (d) Picture of finished device 
diced into a 1 x 0.5 in2 piece. Images are reprinted from [19]. 
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Figure 2.3. Schematic diagram of the confocal laser scanner. Reprinted from [59]. 
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Figure 2.4. Schematic of the objective-coupled, line scanning instrument used to 
acquire fluorescence data at the precise PC resonant angle. Reprinted from [19]. 
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Figure 2.5 (a) schematics of PC structure. Incident angles that are perpendicular to 
grating (Φ) and parallel to grating (θ) are specified. Dispersive curve of PC along (b) θ 
and (c) Φ are provided. Reprinted from [56]. 
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Figure 2.6. (a) Schematic diagram of the protein microarray assay format. Each 
microscope slide is divided into 16 wells and each well consists of 20 capture antibodies. 
(b) A representative fluorescence image of one block for 20+ biomarkers; spot color is 
representative of biomarker concentration. 
(a) 
(b) 
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Figure 2.7 (a) Fluorescence images of protein microarray spots after exposing to a 
mixure of 20 biomarkers. The left image was obtained when PC was illuminated at 
resonant angle while the right image was detected at off-resonance condition. (b) 
Comparison of the replicate-averaged fluorescence intensity at PC resonance and off 
PC resonance for all functional assays in the array. Error bars indicate +/- one standard 
deviation of 8-replicate spots. (Reprinted from [57].) 
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Figure 2.8 Dose-response curves for TNF-a at PC resonance condition (solid curve) and 
off resonance (dashed curve) condition. The detection sensitivity, which is represented 
by the slop in the linear region, is higher at its resonance condition compared to that at 
off-resonance condition. Sensitivity here is defined as the change in fluorescence signal 
per unit change in its concentration. (Reprinted from [57]). 
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CHAPTER 3 APPLICATION OF PHOTONIC CRYSTAL 
ENHANCED FLUORESCENCE TO ALLERGY TEST 
3.1 Chapter Introduction 
We demonstrate detection of low-concentration allergen-specific 
Immunoglobulin E (IgE) in human sera using a Photonic Crystal Enhanced 
Fluorescence (PCEF) microarray platform. The PC surface, designed to provide 
optical resonances for the excitation wavelength and emission wavelength of 
Cy5, was used to amplify the fluorescence signal intensity measured from a 
multiplexed allergen microarray. Surface-based sandwich assays were used to 
detect specific IgE antibodies against a highly purified cat allergen (Fel d1).  A 
comparison of the lowest detectable concentration of IgE measured by the PC 
microarray system and a commercially available clinical analyzer demonstrated 
that the PCEF microarray system provides higher sensitivity. The PCEF system 
was able to detect low concentrations of specific IgE ~0.02 kU/L, which is 5-fold 
to 17-fold more sensitive than the commercially available FDA-approved 
analyzers. In preliminary experiments using multi-allergen arrays, we 
demonstrate selective simultaneous detection of IgE antibodies to multiple 
allergens. The PCEF microarray system holds great promise in future point-of-
care diagnostic tests using very small blood samples from patients with clinical 
allergy symptoms. 
 3.2 Motivation  
In industrial countries, more than 20% of the population suffers from type I 
allergies (i.e. Immunoglobulin E), representing a major health problem in the 
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Western world [60-62]. The clinical evaluation of allergic disorder typically 
involves use of the clinical history, physical examination and a test to confirm 
sensitization to the allergen [63]. Sensitization can be measured by skin testing 
with allergen extracts [64-66] or blood tests [67-71]. A skin test is done by 
monitoring a patient’s reactions after a small amount of a suspected allergen is 
placed on or below the skin, while a blood test is an immunoassay that measures 
the concentration of Immunoglobulin E (IgE) against specific allergens in the 
patient’s blood. Blood tests have several advantages over skin tests. First, they 
are more convenient as they involve only a standard blood draw, and might be 
safer since they are performed in vitro, and thus do not expose the patient to 
allergens [72, 73]. Second, blood tests are performed instead of skin tests for 
patients who have severe symptoms and cannot stop taking medication [74]. 
Moreover, studies have shown that the total amount of IgE against some 
allergens can predict the severity of symptoms [75, 76].   
The currently available analysis systems for blood tests primarily rely upon 
crude allergen extracts prepared from various allergen-containing biological 
materials (e.g. pollens, foods, etc.). These extracts contain a variety of allergenic 
and non-allergenic components and are often difficult to standardize with respect 
to their allergen content or potency. Therefore, extracts-based diagnostics may 
not adequately discriminate between patients who are sensitized to different 
allergen sources [77, 78]. For the same reason, it is difficult to provide accurate 
allergy therapy to individual patients if poorly defined allergen extracts are used 
during diagnostics. However, by applying current protein and DNA technology to 
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the field of allergen identification, it is now possible to produce the major 
allergens for the most prevalent allergies in a purified form [79, 80]. Using these 
purified allergens, each individual patient’s treatment can be tailored according to 
his/her sensitization profile. Since a variety of recombinant allergens is available, 
a comprehensive monitoring of the patient’s IgE reactivity profile to a great 
number of different allergen molecules requires a new type of test that can 
provide multi-allergen detection. 
In addition to the fact that the present platforms fail to meet the 
multiplexing need for personalized therapy, there is substantial interest in 
reducing the limits of detection (LOD) and generally increasing the signal-to-
noise ratio (SNR) in order to diagnose allergies in patients whose IgE levels are 
at very low concentrations. Because specific IgE levels depend on age, total 
serum IgE and the time of year tested, some patients are diagnosed as 
‘‘negative’’ for an allergy due relatively low IgE levels that are below the detection 
threshold of existing technology [81, 82]. Moreover, for point-of-care methods 
with capillary blood, the specimen may need to be diluted below the test 
instrument’s lower limit of quantitation [82, 83]. However, most commercial 
autoanalyzer systems to measure specific IgE have detection limits in the 0.10 to 
0.35 kU/L range (1 U = 2.4 ng) [82, 84, 85]. To achieve the needed sensitivity, a 
platform with sufficient signal amplification, employing highly purified and/or 
recombinant allergens is needed [86].     
As shown in Chapter 2, we have demonstrated a photonic crystal 
enhanced fluorescence (PCEF) microarray system that can achieve high 
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sensitivity for multiplexed cancer biomarker detection at low sample volume [8, 
19, 53]. In this dissertation, we extend the application of the PCEF technology to 
a prototype allergy testing platform to achieve multiplexed, sensitive and specific 
IgE detection. This approach allows successful detection of allergen-specific IgE 
at low concentration, using small volumes of human serum. We found that our 
platform has higher sensitivity than a standard analyzer used for allergy 
immunoassays throughout the world [87]. In addition, the PCEF platform permits 
multiplexing of allergens, provides signal quantification, and detects several 
allergen-specific antibodies simultaneously on a single chip. It holds great 
promise in future point-of-care diagnostics for patients with allergy symptoms.    
3.3 Methods 
3.3.1 PC Fabrication and Characterization 
The PC is designed and fabricated as described in Chapter 2. The PC 
resonant coupling can be observed by measuring the reflected intensity of laser 
illumination as a function of incident angle, as shown in Figure 3.1, where the 
peak reflected intensity corresponds to the angle at which optimal coupling 
occurs. Here, an incident angle of 4.12 o achieves the resonance condition. Our 
previous work demonstrated that the PC also provides a second resonance at 
λ~685 nm that provides an enhanced extraction effect [49].  
3.3.2 Source of Materials 
We sought to test the feasibility of PCEF for selective characterization of 
the presence of allergen-specific IgE using three different allergen materials 
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(Timothy grass extract (Hycor Biomedical), cat hair & epithelium extract (Hycor 
Biomedical) and Fel d1, a highly purified protein from cat extract (Indoor 
Biotechnolgies, Charlottesville). The human sera used in these studies were 
provided by Viracor-IBT Laboratories and Hycor Biomedical, Inc.  These discard 
sera had previously been tested for various specific IgEs with a standard clinical 
analyzer used for allergy testing (ImmunoCAP, ThermoFisher, Fremont CA). 
3.3.3. Preparation and Allergen Printing on the PC Surface 
A single 0.5 x 1.0 in2 PC die holds 10 subarrays, and each subarray 
contains four sets of four replicate spots per protein for a total of 16 spots. 
Before allergen printing, the PC surface was cleaned and activated with a 
vapor-phase epoxysilane process. The epoxysilane chemistry was chosen for 
its low background fluorescence [88] and high binding capacity to capture 
antibodies [89]. The devices were first cleaned by sonication in 2” petri dishes 
of acetone, isopropanol, and deionozied (DI) water for 2 minutes each. The 
devices were then dried in a stream of N2 and then treated in an oxygen plasma 
system (Diener, Pico) for 10 minutes (power of 100 W, pressure of 0.75 mTorr). 
The backside of each device was then adhered to the inside of a screw top lid 
of a 2” glass container. At the base of the container, 100 µL of (3-
Glycidoxypropyl) trimethoxysilane (GPTS, Sigma Aldrich, Saint Louis, MO) was 
placed and the screw top lid was securely placed over the dish. After securely 
tightening the lids, each dish with a device adhered to its lid was placed in a 
vacuum oven for an overnight incubation at a temperature of 80 oC and a 
pressure of 30 Torr. The devices were then detached from the lids and 
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sonicated in 2” petri dishes of toluene, methanol, and DI water for 2 minutes 
each and dried under a stream of N2.  
The allergen microarrays were printed by a commercially available 
instrument (Arrayit NanoPrint LM60 Microarrayer) which provides a controlled 
environment (ambient temperature and 50% relative humidity). Four pins 
(946MP3 Microarray Printing Pins) were used to print the sixteen spots. Printing 
pins were cleaned between sample pickups with 15 s sonication, four cycles of 
washing (2.5 s) in DI water and drying (1 s). Measured spot diameters were 
79.00 ± 2.22 µm.  Row spacing was 149.25 ± 3.26 µm and column spacing was 
200.75 ± 0.82 µm. The printed slides were incubated in a sealed box with a 
desiccant overnight at ambient temperature before use.    
It is well known that proteins deposited onto solid surfaces display 
distinct characteristics due to differences in charge, molecular structure, acidity, 
specificity, affinity, hydrophobicity and stability. The diversity of protein 
structures poses a challenge for identifying a universal assay surface that 
maintains capture protein functionality equally for all the capture probes in a 
microarray, as discussed in the literature [90, 91]. In this dissertation, we 
studied the optimized spotting concentrations by incubating the serum with 
different concentrations of allergen spots. Both allergen extracts (cat and 
Timothy grass extract) and a highly purified allergen (Fel d1) were used to 
produce the probe spots.  Fel d1 is the major allergen in cat hair and epithelium 
extracts, and is expected to have better specificity than the cat extracts, which 
are complex mixtures of proteins. The initial protein concentrations for the cat 
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extract were 0.22 mg/mL, 1.3 mg/mL and 3.4 mg/mL respectively. Each of the 
allergen solutions was spotted over four concentrations in a two-fold dilution 
serial and each subarray had 16 spots with four replicate spots per each 
concentration. A fluorescent image of the assay that was incubated with 
positive sera was used to identify the printing concentration with the highest 
fluorescent intensity. The results (Table 3.1) indicate that the highest 
concentration was optimal for these three allergens to obtain strong fluorescent 
signals. Therefore, allergen spots were printed at the highest available 
concentrations for the remainder of our study. 
Table 3.1. Fluorescence intensities at different printing concentrations 
Printing concentration Average signal from 
cat extract spots 
Average signal from 
Fel d1 spots 
Average signal from 
grass extract spots 
Original concentration 10365±1544 23482±212 11089±228 
2-fold dilution 5971±310 17342±3900 6114±342 
4-fold dilution 3169±337 16525±2689 4450±1415 
8-fold dilution 3821±260 13001±2408 2644±188 
 
3.3.4 Testing Procedures  
The slides were placed in a 10-well custom-made slide module assembly 
(Figure 2(b)) where each well can hold a 10 µL test sample.  The arrays were 
blocked with a blocking buffer that contains 10 mM sodium phosphate, 0.5 M 
sodium chloride, 0.02% (w/v) tween 20, 1% (w/v) human IgG, 25% (w/v) human 
serum albumin and 1% (v/v) ProClin 950 (Hycor Biomedical, Inc.) for 1 h.  All 
incubations were performed at room temperature.  The arrays were then 
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washed five times with a wash buffer that contains 4.5% (w/v) NaCl, 0.25% (v/v) 
Tween-20, 15% (v/v) Propylene glycol and 0.05% (v/v) ProClin 950 (Hycor 
Biomedical, Inc.).  Next, each well was incubated with 10 µL human serum or 
serum dilution in blocking buffer overnight. This was followed by five rinses after 
which the PC surface was incubated with only 10 !L of the biotinylated 
detection antibody mixture (mouse monoclonal B3102E8 anti-human IgE and 
mouse monoclonal HP8029 anti-human IgE, at the mixing ratio of 1:1, Abcam 
Inc.) in each well of the slide module assembly for 4 hours. The PC substrates 
were then washed five times followed by incubation with a 1 µg/mL solution of 
Cy5 conjugated streptavidin (Invitrogen) for 30 minutes. Finally, the devices 
were washed five times and dried in the ambient environment.  
3.3.5 Image and Data Acquisition 
The substrates were scanned with a commercially available confocal laser 
microarray scanner (Tecan LS Reloaded, as described in Chapter 2). This 
scanner was fitted with a 632.8 nm 5 mW laser for Cy5 excitation and a Cy5 
emission filter (bandpass, 670-715 nm). The incident light was TM polarized and 
made incident on the substrates at an angle of 4.12o so that maximum laser 
coupling efficiency could be achieved. Scans were obtained at a resolution of 
10!!m and the photomultiplier tube (PMT) gain was adjusted to 80 so that the 
largest fluorescence intensities did not saturate the PMT. Fluorescent images 
were analyzed using ImageJ to compute spot and local background intensities as 
well as standard deviations for each spot. 
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3.4 Results 
3.4.1 Selectivity of the Assay  
We constructed a testing well on the PC chip by creating four-plexed 
allergen arrays for simultaneous allergen-specific IgE antibody detection with 
low sample volumes (10 !L). As shown in Figure 3.2(a), the first row is cat hair 
extract, the second row is Fel d1, the third row is Timothy grass extract and the 
last row is Alexa-Fluor-555 fluorescent streptavidin conjugates to identify 
location of protein spots (Life technologies). As discussed earlier, the cat hair 
extract, the Fel d1 allergen, the Timothy grass extract and the positive control 
were printed at concentrations of 0.22 mg/mL, 1.3 mg/mL, 3.4 mg/mL and 10 
ug/mL respectively.  
To validate our platform using low sample volumes, we obtained serum 
samples that had been tested previously with a standard clinical immunoassay 
analyzer. Approximately 10!!L of human serum was used to expose the PC 
arrays. After processing, we analyzed the chips in a microarray scanner to 
detect and quantify the signals. Some of the rows of spots had high variances 
across spots after quantifying the fluorescence images. This issue is possibly 
related to problems with sample application and washing in the prototype 
platform or with the allergen extract variabilities. 
The assays exhibited excellent selectivity. If a patient’s serum contained 
specific IgE antibodies against one or more allergens, we detected positive 
signals specifically on the respective allergen spots. With this technique, we 
were able to distinguish the serum samples with different amounts of grass-
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pollen and Fel d1 specific antibodies (Figure 3.2(c)). For example, as shown in 
Figure 3.2(d), we detected strong fluorescence on grass pollen spots for 4-fold 
dilution of serum #85228 which had high-level grass-pollen specific antibodies, 
while the fluorescence was invisible for 4-fold dilution of serum #924365 that 
had a concentration less than 0.1 kU/L. In addition, we observed fluorescence 
from Fel d1 spots for both sera that was previously shown to contain IgE 
antibodies against Fel d1. No fluorescence was detected for either grass pollen 
or Fel d1 spots in the cases of negative serum incubation. 
3.4.2 Sensitivity of the PCEF Array System 
Two human sera (serum #85228 and #924365) that contain cat hair-
specific IgE were tested over a range of eight concentrations in a 2-fold dilution 
series. To assess the sensitivity of IgE testing by PC microarray, the same 
original sera were also analyzed by ImmunoCAP, an automated instrument 
system widely used for allergy testing [92, 93].  
The fluorescent images of microspots at different antibody 
concentrations are presented in Figure 3.3. Note that Fel d1 spots have higher 
fluorescence intensities than cat extract spots for the same serum dilution, 
which confirms that purified allergen has stronger binding affinity and thus 
higher sensitivity than the crude extracts. To quantitatively characterize how 
easily a spot can be distinguished from the noise, we define signal to noise ratio 
(SNR) as the net signal intensity divided by the standard deviation of the 
background intensity. A spot with SNR larger than 3 is regarded as detectable. 
Figure 3.3 shows that all of the Fel d1 spots were detectable over the 0.005 – 
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4.000 kU/L range. Even the average SNR over four Fel d1 replicates at the 
lowest concentration (0.005 kU/L) is 5.16. However, in order to determine the 
lowest detectable concentration, we need to create a dose response curve and 
compare fluorescence intensities at different concentrations with the 
background intensity. 
The signal intensities from each dilution in the concentration series were 
used to generate a standard curve (Figure 3.4) for the Fel d1 allergen using 
Origin. The limit of detection (LOD) is defined as the concentration 
corresponding to the background intensity that is the blank intensity (i.e., the 
intensity of the negative control spot of diluent) plus 3 standard deviations from 
all assay spots. Negative controls performed by exposing the capture allergens 
to a negative serum sample resulted in no observable fluorescence signal 
above the background. The black solid line in the inset represents the 
background intensity, while the dashed line indicates the blank intensity from 
the negative control. From the inset of Figure 3.4, we can tell that fluorescence 
intensities from Fel d1 spots assayed with diluted sera with antibody 
concentrations of 0.005 kU/L and 0.011 kU/L were below the background 
intensity although they were observable in the image. Therefore the LOD value 
for antibody specific to Fel d1 is ~0.02 kU/L, which is lower than the lowest 
detectable concentration of 0.1 kU/L measured by ImmunoCAP system. With 
regard to the model allergen used, PCEF technology appears to be more 
sensitive than the ImmunoCAP system.  
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Fluorescent images of grass-positive serum (Serum#85228, Figure 3.5) 
were also used to characterize the LOD value for grass extracts. The starting 
serum is diluted by 2 times. As shown in Figure 3.5, the 32-folds serum dilution 
is the lowest detectable one, since the three highest dilutions are all below the 
lower bound of the fitted curve. The strong fluorescence from the dilutions that 
were below the detection limit is likely due to the non-specific binding from the 
crude extracts. We expect the availability of the purified grass allergen will 
results in lower detection limit using the PCEF system. 
3.4.3 Calibration of Assay: Translating PCEF Readings into IgE 
Concentrations 
To facilitate the use of the described PCEF assay in clinical labs, we 
calibrated the assay by reference to specific IgE concentrations determined by 
the ImmunoCAP assay. This assay generates results in kU/L specific IgE and is 
based on a IgE curve using an international standard IgE preparation. The kU/L 
results are used by clinical allergists to stratify their patient sensitivities and to 
make decisions about treatment.  By fitting the standard curve in Figure 3.4, a 
four-parameter logistic function was derived as 
! = !"!#$.!(!!!"!.!(!.!! !"# )) + 865.7, (3.1) 
where F is the fluorescence intensity and !"#  is the concentration of the 
antibody. Using equation (3.1), we were able to calculate the IgE concentration of 
a serum sample by detecting the fluorescence intensity of its specific allergen 
spots. The previous sera that were used to generate the standard curves were 
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tested again on each PC chip in order to normalize intensities across chips for 
the other assays. The fluorescence signal from the immunoassay that has the 
smallest deviation from the value in the standard curve was used for 
normalization.  
3.4.4 Application of Calibrated Results to Additional Sera 
We obtained human sera from 15 individuals for whom we had 
previously determined specific IgE values and used the PCEF microarray 
system to test them. Fluorescence images were analyzed and their readings 
were translated into values of antibody concentrations. Figure 3.6 contains 
representative images of the allergen spots assayed with sera at various Fel 
d1-specific IgE levels ranging from 0.089 kU/L to 40 kU/L. These IgE levels 
were measured by the ImmunoCAP system. The calculated concentrations of 
Fel d1-specific antibody from the PCEF array system are shown in Table 3.2. 
Note that Fel d1-specific IgE in serum #9 was only detectable by the PCEF 
array system, which confirms its high sensitivity. The deviation of calculated IgE 
levels between the PCEF array system and ImmunoCAP system might be 
attributed to differences in surface chemistry, allergen activity after binding, 
fluorescence reporter and detection instrument. 
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Table 3.2. Autoantibody concentrations from 15 serum samples 
measured by the ImmunoCAP system and PC microarray system  
Serum Number 
Fel d1 ImmunoCAP Value 
(kU/L) 
Fel d1 PC Microarray Value 
(kU/L) 
1 0.835 0.497 
2 0.645 1.486 
3 1.345 2.422 
4 1.680 1.467 
5 1.475 1.189 
6 2.385 2.966 
7 BLOD* BLOD 
8 BLOD BLOD 
9 BLOD 0.089 
10 5.920 6.816 
11 4.000 8.520 
12 6.300 15.594 
13 5.240 13.216 
14 4.560 4.134 
15 40.000 28.986 
 
* BLOD means the concentration of Fel d1-specific IgE is below LOD. 
 
3.5 Conclusion 
Allergy blood tests measure levels of IgE against specific allergens such 
as foods, inhalants, medications, latex and venoms. These tests can confirm 
the diagnosis of an allergy disorder, supplementing a clinical history consistent 
with an immediate allergic reaction. Unfortunately, recognition of some food or 
inhalant allergens by IgE, which constitutes the least abundant class of 
immunoglobulins, requires a highly sensitive detection platform that is not 
currently available commercially. In addition, multiplexing capability is needed to 
fulfill the requirements for component-resolved diagnostics and personalized 
therapies.   
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In this work, a PCEF microarray platform successfully detected low-
concentration IgE in human sera. The PC surface designed to provide optical 
resonances for the excitation wavelength and emission wavelength of Cy5 was 
used to amplify the fluorescence signal intensity measured from a multiplexed 
protein microarray. A surface-based sandwich assay was used in which 
secondary antibodies were exposed to the array after analyte hybridization, 
while a SA-Cy5 label was used to tag the secondary antibodies. Comparison of 
the LOD measured by a commercially available antibody analyzer to the PC 
microarray system clearly demonstrates that the PCEF microarray system 
provides lower limits of detection. Dose-response characterization of the assays 
demonstrates a lowest detectable concentration of 0.02 kU/L for Fel d1-specific 
IgE. In addition to the high sensitivity, the PCEF microarray platform allows 
simultaneous detection and quantification of antibodies to various allergens. 
While ImmunoCAP testing requires several milliliters of blood, the microarray 
platform requires only 10 !L of serum, for compatibility with less invasive 
sample collection via a finger-prick method.  Finally, our results demonstrate the 
efficacy of using purified allergen components as the selective capture agent, 
which delivered greater sensitivity and reproducibility than raw allergen extracts. 
In addition to addressing the current clinical need for improved allergy 
testing, we believe that this technology will enable a broad range of advances in 
basic and clinical research that were not previously feasible. For example, serial 
monitoring of antibodies in patients undergoing new treatment might predict the 
effectiveness of the therapy, as the IgE levels might correlate with the severity 
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of the patients’ symptoms. Furthermore, tracking antibody levels at high 
resolution in high-risk patients would yield great insight into the onset of allergy 
symptoms. Ultimately, we believe that this technology could be deployed to 
facilitate screening for allergen-specific IgEs and preventative therapies.  
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3.6 Figures  
!
Figure 3.1. Reflection spectrum of PC when it is illuminated by a Transverse Magnetic (TM) polarized 
laser at the wavelength of !!= 637 nm. The peak location of the spectrum indicates the resonance 
condition is achieved at the incident angle of 4.12 o. 
!
!
58!
 
!
Figure 3.2. (a) A PC holds 10 subarrays, and each subarray contains four sets of four replicate 
spots per protein for a total of 16 spots. Inset: schematic of the microarray layout. The first row 
is the cat hair extract, the second row is the Fel d1, the third row is the Timothy grass extract 
and the last row is a set of array location fluorescent spots comprised of Alexa-Fluor-555 
fluorescent streptavidin conjugates. (b) A 10-well format custom-made slide module assembly 
in which the PC is inserted during the assay steps. (c) Fluorescence images of the arrays 
tested with different sera. (d) Average fluorescence intensities from Fel d1 and Timothy grass 
spots. The result indicates that the Fel d1 and grass pollen assays exhibited excellent 
selectivity. Strong fluorescence was observed on grass pollen spots for 4-fold dilution of serum 
#85228 which has a high concentration of grass-pollen specific antibodies, while no fluorescent 
signal is observed for 4-fold dilution of serum #924365 that has low concentration. No 
fluorescence was detected on either grass extract or Fel d1 spots in the case of negative serum 
incubation.!
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Figure 3.3. Fluorescent images of microspots at different antibody 
concentrations for (a) a serum sample provided by Hycor and (b) a serum 
sample provided by ViraCor-IBT. Fel d1 spots have higher fluorescence 
intensities than cat extract spots, confirming that purified allergen has stronger 
binding affinity and thus higher sensitivity than crude extracts. The images also 
indicate that all the Fel d1 spots were visible over the 0.005 – 4.000 kU/L range. 
For example, average SNRs over four Fel d1 replicates at the lowest 
concentration (0.005 kU/L) is 5.16. 
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Figure 3.4. Standard curve for Fel d1 allergen detection. The black solid line in 
the inset shows the background intensity, which is the blank intensity from the 
negative control (indicated by the dashed line) plus three times the standard 
deviation. We consider fluorescence signals above the background intensity as 
detectable. Therefore, the lowest detectable concentration for Fel d1-specific 
antibody is ~0.02 kU/L, which is lower than that measured by the ImmunoCAP 
system. 
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Figure 3.5. Does response curve for the grass extracts. Grass-positive serum 
was tested over a range of 8 concentrations in a 2-fold dilution series. The 
starting serum is diluted by 2 times. As shown in the figure, the detection limit is 
32-fold dilutions serum. 
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!
Figure 3.6. Representative images of the allergen spots assayed with patient 
sera at various IgE levels ranging from 0.089 kU/L to 40 kU/L. Note that the 
PCEF array system is capable of detecting the low concentration of IgE in serum 
#9, which is not observable using the ImmunoCAP system.!
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CHAPTER 4 PHOTONIC CRYSTAL ENHANCED FLUORESCENCE 
MICROFLUIDIC CHIP FOR HIGH SENSITIVITY AUTOMATED 
MULTIPLEXED IMMUNOASSAYS 
4.1 Chapter Introduction 
We demonstrate a platform that! integrates photonic crystal enhanced 
fluorescence (PCEF) detection of a surface-based microspot fluorescent assay with a 
microfluidic cartridge to achieve simultaneous goals of high analytic sensitivity (single-
digit pg/mL), high selectivity, low sample volume, and assay automation. The PC 
surface, designed to provide optical resonances for the excitation wavelength and 
emission wavelength of Cy5, was used to amplify the fluorescence signal intensity 
measured from a multiplexed biomarker microarray. A plastic microfluidic device for 
holding the PC was created using a low-cost and flexible process. An assay automation 
system that utilizes a leak-free fluid interface was built to introduce the correct sequence 
of fluids through the microfluidic device. Through the use of the assay automation 
system and the PC embedded within the microfluidic device, we demonstrate pg/mL-
level limits of detection by performing a representative biomarker assay (for IL3 and 
TNF-α). The results are consistent with limits of detection achieved without the use of 
the microfluidic device with the exception that coefficients of variability from spot-to-spot 
are substantially lower than those obtained by performing assays with manual 
manipulation of assay liquids. The system’s capabilities, when fully developed, are 
compatible with the goal of diagnostic instruments for point-of-care settings. 
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4.2 Motivation 
Rapid detection of immune-related biomarkers in serum or plasma to 
pathogenic antigens, tumor antigens, or autoimmune antigens, is critical for diagnosis, 
monitoring, and biomarker assessment of the immune response [28, 94]. In addition, 
soluble protein biomarkers in blood have also been useful for understanding the form 
of a disease that can be most effectively treated by a particular drug [95]. Both of 
these technologies facilitate the combination of therapeutics with diagnostics as a 
means of guiding treatment for an individual patient [96].  Biomarker detection is used 
most heavily in oncology for early detection of several forms of cancer [97-105] and as 
a tool for companion diagnostics, but it also has significant application in other 
diseases with high unmet needs. For example, biomarkers for cardiovascular disease 
[106, 107], autoimmune disease [28], neurological disorders, and infectious disease 
have been identified and are undergoing clinical validation [108]. 
A key unmet need for biomarker detection to achieve clinical relevance is 
improved sensitivity.  Early diagnostic applications for cancer, for example, require 
detection of biomarkers that are produced by, or in response to, a small number of 
cells. The biomarker is diluted throughout the volume of blood within a person, so that 
when a sample of peripheral blood is drawn, the biomarker concentration can be <1-10 
pg/mL.  (For reference, 1 pg/mL of a typical cytokine such as IL-6 is equivalent to ~45 
fM.  A 10 µl sample at this concentration contains 0.45 attomoles of IL-6.) In addition to 
high sensitivity, clinical diagnostic laboratories require automated, high-throughput 
platforms that can perform rapid multiplexed biomarker analysis at low cost/assay and 
that can quantify small changes in concentration.  Consensus is emerging that 
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multiple, mutually exclusive biomarkers in an assay will lead to better clinical 
management of disease, compared to assessment of a single biomarker, and will 
allow subtle differences in patient populations (gender, race, age) to be understood 
[20-22]. 
Among the current methodologies of biomarker detection, sandwich antibody 
microarrays hold great potential because of their capability to detect analytes at <10 
pg/mL concentration [28, 109] with the use of 3-10 µL of sample, no assay cross-
reactivity, and fast binding kinetics. Using a photonic crystal (PC) surface to enhance 
the fluorescence output from a biomarker microarray, we have published a number of 
studies that successfully achieved high sensitivity for multiplexed cancer biomarker 
detection [8, 17, 19, 53]. More recently, we developed a high sensitivity, compact, and 
inexpensive detection platform that used a silicon-based PC surface and a custom 
laser line-scanner in an effort to minimize the background auto-fluorescence and 
maximize the coupling efficiency of light into PC structure [19]. Microspot fluorescent 
immunoassays for TNF-α and IL-3 performed on this platform demonstrated that the 
system can achieve pg/mL-level sensitivity. Although only a 10 uL sample was 
consumed with the use of 2 mm-diameter microwells, manual sample handling 
presented difficulties in injecting liquid, required dedicated time and labor, and 
introduced bubbles that were difficult to remove and decreased the incubation 
efficiency. Furthermore, the performance and implementation characteristics of 
performing PCEF microarray assays with manual liquid sample handling greatly limited 
its scalability and accessibility to clinicians, including a disjointed workflow that 
required manual intervention across multiple steps and used the PC surface area 
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inefficiently. Therefore, the development of a simpler and automatic format is desired 
for clinical applications such as point-of-care diagnostics. 
Here we present a new platform that! combines photonic crystal enhanced 
fluorescence (PCEF) and microfluidic sample handling to achieve high analytic 
sensitivity (1.57 pg/ml), high selectivity, low sample volume, and assay automation. A 
low-cost and flexible process that combines stereolithographic 3D printing [110-112] 
and laser-cutting [113-115] was developed to create a plastic microfluidic device for 
holding the PC in place during an assay and for providing a stable platform during the 
fluorescence scanning. An assay automation system that involves a custom built, leak-
free fluid interface was built to introduce the correct sequence of fluids through the 
microfluidic device. We performed a representative biomarker assay and 
demonstrated 1.57 pg/mL level detection sensitivity with the use of the assay 
automation system and the PC embedded microfluidic chips. The coefficients of 
variability across spots are decreased for the low concentration assays compared to 
previous results. This rational engineering design strategy incorporates innovative 
elements that are required for a system that can rapidly provide information in a 
clinical setting, thereby potentially allowing for quicker, more personalized medical 
intervention.   
4.3. Materials and Methods 
4.3.1 Design and Fabrication of a PC-Embedded Microfluidic Device 
The PC is designed and fabricated as described in Chapter 2. An SEM image 
showing the surface structure of the PC is presented in the inset of Figure 4.1(d). As 
shown in Figure 4.1(a), the microfluidic chip was assembled using a stack of plastic, 
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Double-Sided Adhesive (DSA), and a nonfluorescent glass coverslip. The top plastic 
layer was designed by three-dimensional (3D) design software (PTC Creo Parametric 
2.0) and fabricated by stereolithography of optically clear resin (WaterClear Ultra 
10122). Stereolithography is a high-speed optical fabrication process in which model 
layers are built by curing photo-reactive resin with a laser. A Viper SLA System was 
chosen for its high resolution (2.5 !m) and small laser beam diameter (75 !m), which 
was critical to fabricate a precise microfluidic device. The top layer was 75 mm long, 25 
mm wide, 6 mm thick, and contained a recessed region (2.2 mm!x 8.2 mm), into which 
the PC chip of the same dimension was attached by adhesive. Two through-holes 
extend through this top layer to serve as fluid inlets/outlets. The middle layer was 
comprised of DSA (3M™ Optically Clear Adhesives 8212) with a ~2 x 12 mm wide and 
150 !m thick channel in the center which matched the shape of the fluid inlet/outlet and 
the PC.  In order to ensure device cleanness, accurate non-contact laser cutting was 
used to cut the channel area on the DSA. The bottom layer is a thin transparent 
coverslip through which a camera monitored flow inside the channel and a laser excited 
the fluorophores during the detection stage. Shott Glass (#1098576 24 x 60 x 0.17 mm) 
was chosen for its tight thickness tolerance, which minimizes spherical aberration, and 
its low background fluorescence, therefore promoting high-quality images of the 
fluorescence signal during scanning. The three layers were attached by the DSA layer 
in a custom-built mechanical alignment fixture and pressed by a roller at room 
temperature to seal them together. Figure 4.1(c) shows a photo of a fabricated 
microfluidic chip in which red food dye was introduced through the inlet. 
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4.3.2 Computer-Controlled Microfluidic System 
Using components shown in Figure 4.2(a), the entire assay process was 
automated with no intervention from the user other than introduction of a droplet of 
serum into the inlet reservoir (volume ~10 µL). The 3-to-1 valve (Cole-Parmer Manifold 
Mixing Solenoid Valve) introduced compressed air, buffer solution, or detection antibody 
labeled with Cy5 into the channel. The fluid selection was determined by an automated 
and programmable microfluidic controller (FlowTest™ Programmable Microfluidic 
Controller). The fluid driving force was supplied by compressed nitrogen, which was 
regulated by a pressure controller (Fluigent MFCS-EZ) that provided pulseless and 
highly stable (<0.1% CV) flows.  A digital camera (Dino-Lite AM3111T) located beneath 
the fixture monitored the flow through a hole in the fixture. Users can control the 
pressure and microfluidic flow through a computer, and users can also monitor the flow 
on-screen from the camera. 
To ensure leak-proof sealing and zero dead volume, flanged end tubes and a 
custom-machined metal frame were used in our system [116]. The seal was based on a 
forced fit between the flanged ends of chemically inert polytetrafluoroethylene (Cole-
Parmer PTFE EW-06605-27 1/16’’) tubing and the flat outer surface of the microfluidic 
chip. The flange was created by heating the end of the tubing and pressing it against a 
metal washer. The metal frame maintains alignment between the tubing and the 
inlet/outlets of the microfluidic chip, while screws between the upper and lower metal 
holding plates of the fixture apply sufficient pressure for a leak-proof seal. A schematic 
of the sealing fixture is shown in Figure 4.2(b). 
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4.3.3 Immunoassay Procedure Using Microfluidic Sample Handling 
To demonstrate the capability of the microfluidic system, microspot 
immunoassays for two cytokines (interleukin 3 (IL-3) and tumor necrosis factor alpha 
(TNF-α)) were performed using PCs embedded in the microfluidic device. Before 
printing spots, the PC surface was cleaned and activated with a vapor-phase 
epoxysilane process as described in Chapter 3. After silanization, the protein arrays 
were printed onto the PC surface. A PC holds two subarrays, and each subarray 
contains four sets of four replicate spots for each protein, resulting in an array with 16 
spots. The first row is a fluorescent-tagged protein for array orientation/location (Alexa-
Fluor-555 fluorescencent streptavidin conjugates, Life Technologies), the second row 
is the TNF-α antibody (R&D systems Inc.), the third row is a negative control (PBS, pH 
= 7.4), and the last row is the IL-3 antibody (R&D systems Inc.). The antibody 
microarrays on the PC were printed by a desktop nanofabrication system (Arrayit 
NanoPrint LM60 Microarrayer) while the chip was in a free format. The printing was 
performed under a controlled environment using an environmental chamber (ambient 
temperature and 50% relative humidity). Four pins!(946MP3 Microarray Printing Pins) 
were used to print the two cytokines at a concentration 1 mg/mL, the positive control at 
10 µg/mL, and the negative control on an epoxysilane modified PC. Printing pins were 
cleaned between sample pickups with 15 s sonication and four cycles of washing (2.5 
s) and drying (1 s). Measured spot diameters were 79.00 ± 2.22 µm. Row spacing was 
149.25 ± 3.26 µm and column spacing was 200.75 ± 0.82 µm. The printed substrates 
were incubated in a sealed box with a desiccant overnight at ambient temperature. 
Next, the arrays were blocked with casein blocking buffer (BioRad, Hercules, CA) for 1 
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h before they were washed three times with 0.02% (v/v) tween 20 in PBS (PBST). The 
substrates were then dried and put in a sealed box for future use.  
Following array printing and surface blocking, a PC substrate with antibody 
microspots was glued into the recess of a plastic holder that was made by 
stereolithography. This PC embedded plastic layer was then bonded to a glass cover 
slip by a DSA layer with the channel pattern to complete the fabrication process. After 
that, this complete microfluidic device was used to perform the immunoassay for 
mixtures of different antigen concentrations in casein buffer. Ten µL of the mixture of 
TNF-α  and IL-3 was manually introduced into the microchannel inlet by a pipette and 
incubated for 3 hours. The hydrophilic property of the inner channel surface facilitates 
liquid flow, so the droplet of test sample covers the PC array without any intervention 
from the user. The cytokine TNF-α (R&D systems Inc.) was assayed at the following 
seven concentrations: 1 ng/mL, 0.25 ng/mL, 62.50 pg/mL, 15.62 pg/mL, 7.8 pg/mL, 3.9 
pg/mL, 1.9 pg/mL. The concentration of IL-3 is 10 times higher than that of TNF-α 
(R&D systems Inc.) in all assayed antigen mixtures. The microfluidic device filled with 
the test sample was then loaded in the assay automation system, so that the wash 
and the labeling steps can be performed.  The device was washed by flowing PBST 
for 1 min with an applied pressure of 25 mBar to remove the unreacted antigens. Next, 
the 1 ug/mL fluorescent-labeled secondary antibody solution (Alexa Fluor® 647 Goat 
Anti-Human IgG, Life Technologies) was introduced into the microchannel with an 
applied pressure of 25 mBar for 30 s. After 1 h incubation, the microchannel was 
washed again by flowing PBST for 1 min to remove the unreacted fluorescent-labeled 
secondary antibody solution. Finally, an air flow was produced in the microchannel by 
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applying high-pressure Nitrogen gas (345 mBar) to the inlet to remove remaining 
liquid. The PC surface was completely cleaned and dried in 10 s due to its 
hydrophobicity, as observed by the imaging camera. Following the immunoassay 
process, the microfluidic chip was removed from the automation system and 
transferred to our customer-built scanner for fluorescent imaging. 
4.3.4 PCEF Scanner and Image Acquisition  
We have designed and constructed a PCEF microarray detection instrument that 
provides collimated illumination and the ability to tune the incident angle to precisely 
match the resonant coupling condition [59] while focusing the light from a fiber-coupled 
semiconductor laser to an 8 µm line with a cylindrical lens [117]. A custom detection 
instrument was built to optimize coupling of laser illumination to the PC surface.  As 
described previously in Chapter 2, the excitation laser is collimated in the plane 
perpendicular to the grating lines, but focused in the plane parallel to the grating (Figure 
4.3). Collimated light with electric field polarization perpendicular to the grating lines is 
able to couple most efficiently with the PC resonant mode, but the light need only be 
collimated with respect to a single axis.  Along the orthogonal axis, light can be focused 
without compromising coupling efficiency to the PC, and thus focus along one axis is 
used to achieve high illumination intensity. The system is designed for optimal 
interaction with the PC for both enhanced excitation and enhanced extraction, using 
design principles discussed, modeled, and demonstrated  in reference [19].  The focal 
point of the cylindrical lens is located at the back focal plane of the objective, resulting a 
line of illumination in the PC that is collimated along the angle perpendicular to the PC 
grating lines, but focused in the orthogonal direction.  Linear translation of the cylindrical 
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lens results in adjustment of the incident angle to achieve ‘‘on resonance’’ illumination.  
A semiconductor laser diode (AlGaAs, 70 mW, λ = 637 nm) is expanded to a diameter 
of 1 mm, and focused to an 8 µm wide line onto the PC surface by a cylindrical lens. A 
mirror coupled to a computer-controlled linear translation stage enables adjustment of 
the incident angle from 0-20 degrees with 0.01 degree increments.  The grating lines of 
the PC are oriented perpendicular to the scan line, allowing the laser (polarized output 
perpendicular to the grating) designed to excite the TM mode of the PC.  
Using the scanner described above, a fluorescent image of the PC surface was 
obtained by adjusting the incident angle of the laser illumination line upon a region of 
the PC adjacent to the microspots and then translating the PC holding stage in 
increments of 2 µm past the array region, gathering a fluorescent intensity image of 
the line for each motion increment. Then, the fluorescent images of each line were 
assembled into a two-dimensional image of fluorescence intensity by using a custom-
built C# user interface.  Spot segmentation and intensity calculations of the 
constructed fluorescence images were performed using ImageJ. Net spot intensity 
was calculated as the local background subtracted spot intensity where the local 
background is an annular region around a given spot. Spot signal-to-noise ratio (SNR) 
was calculated as the local background subtracted spot intensity divided by the 
standard deviation of the local background. 
4.4. Results and Discussions 
4.4.1 Raw Fluorescent Intensity 
Even if fluorescence was detected through the glass window, its influence on the 
fluorescent images and the final assay result is hardly observed, indicating that it is not 
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necessary to remove the glass to perform any scans. From the viewpoint of operating 
procedure simplicity, this is a big advantage that other fluorescent microfluidic devices 
do not have. In order to quantitatively show this, we investigated the effect of scanning 
through the glass window on the fluorescence intensity of the microarray image. In the 
experiment, we performed the immunoassay of 1.9 pg/mL TNFα solution using the PC-
embedded microfluidic device, and we scanned the microarrays before and after 
removing the glass window. The illumination angle (incident angle = 4.12 degree) and 
camera settings (sensitivity gain = 25, exposure time = 40 ms) were the same for both 
scans. Although we scanned the same area twice, the intensity decay after the first 
scan is less than 0.001% [118] and can be safely ignored. This is because the laser 
only illuminated the area for 120 ms, given that the exposure time of the camera was 40 
ms and oversampling rate was 3. Fluorescence intensities of each microspot and its 
surrounding background were obtained by quantifying fluorescent images (Figure 
4.3(a)), and subsequently averaged over the four replicates. Interestingly, the spot 
intensity obtained by scanning through the glass window (the first red bar in Figure 
4.3(b)) is 19.93% higher than that without any obstacle (the first black bar in Figure 
4.3(b)). The increased intensity was attributed to the fluorescence from the glass 
window. In addition to autofluorescence, fluorescence from a small amount of 
fluorescently labeled secondary antibody that was absorbed onto the glass during the 
assay procedure was also a contributing factor. We can confirm this assumption by 
examining the average background intensity, which decreased from 2236.64 counts to 
1744.08 counts by removing the glass (Figure 4.3(b)). Net intensity was calculated as 
the background subtracted spot intensity, through which any fluorescence from the 
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glass was removed. In contrast to the increase in the average spot intensity and 
background intensity, the average net intensity decreased to 93.23% if spots were 
scanned through the glass (the third bars in Figure 4.3(b)). This small signal loss was 
caused by light reflection at the interface between air and glass. Given that refractive 
index is n1 = 1.00 for air and n2 = 1.50 for glass, the transmittance of the fluorescence 
after passing the upper surface of glass is 96.00%, calculated by the equation: 
T = 1− !!!!!!!!!! !  . 
Ignoring the phenomena of multiple internal reflection in the glass, transmittance of the 
fluorescence through the glass, adding the signal loss at the second surface, is 92.16%, 
which is close to the percentage of the signal we obtained in the experiment. 
Considering the small thickness and good flatness of the glass, any absorption or 
scattering can be neglected. Although there was a slight decrease in the net 
fluorescence signal, the fluorescent spots were still distinguishable from the 
background, even for the assay with the lowest concentration.  
4.4.2 Fluorescence Enhancement of a PC-Embedded Microfluidic Device 
The PC is designed to increase the fluorescence intensity of Cy5 dyes through 
the enhanced excitation and extraction mechanism described previously. The 
enhanced extraction effect is always present, regardless of the illumination conditions. 
In a previous report [8], we demonstrated that enhanced extraction resulted in an 
approximately 4.8-fold increase in fluorescence intensity compared to detection on 
unpatterned glass. The effect of enhanced excitation can be determined by comparing 
the fluorescence output under the following two conditions: (a) when the incident angle 
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of the excitation laser was adjusted to illuminate the PC at the resonant angle (‘‘on 
resonance’’), and (b) when the angle of incidence was selected not to coincide with the 
resonant coupling condition (‘‘off resonance’’). Although fluorescence enhancement by 
a silicon PC has been demonstrated previously [19], it is still necessary to characterize 
the enhancement factor and show that the same enhancement can be observed using 
a PC embedded in a microfluidic device that is covered by a glass window. In the 
experiment to characterize the enhanced excitation of the PC in the microfluidic 
device, 0.15 ng/mL of IL-3 was assayed, and the microspots were scanned at both on- 
and off-resonance conditions. First, the reflection spectrum of the PC (Figure 4.4(c)) 
was acquired by illuminating the surface over a range of incident angles at the fixed 
excitation wavelength λ = 637nm. The on-resonance angle of illumination was 
approximately 4.12 degrees, as indicated in the spectrum, while the off-resonance 
angle was chosen to be 3.00 degrees. The fluorescent images shown in Figure 
4.4(a)(b) were obtained at on- and off-resonance conditions, respectively. Because of 
the low fluorescence at the off-resonance condition, exposure time of the camera was 
set to be 400 ms, 10 times higher than that of the on-resonance condition. Therefore, 
the on-resonance value was multiplied by a factor of 10 before direct comparison to 
the off-resonance value. It can be observed in Figure 4.4(d) that by scanning the PC at 
its resonant angle, the fluorescence intensity was enhanced by a factor of 
approximately 26, which is similar to what was reported previously [8, 118]. In general, 
we expect a PC embedded in a microfluidic chip to perform identically to a PC in the 
“free” chip format, as the absorption and reflection of light by the thin glass cover are 
minimal.         
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4.4.3 Standard Curves and Limit of Detection 
The performance of the PC-embedded microfluidic chip was studied in the 
context of a microspot-based fluorescent sandwich immunoassay. Seven 
concentrations of antigen mixtures were assayed by the PC microfluidic system as 
described in the previous sections. Because of the flanged tube that connects the 
microchannel to the control instrument, no liquid leakage was observed throughout the 
process. The assay procedure was controlled by a computer with minimal human 
intervention, which makes it highly repeatable. Figure 4.5(a) shows representative 
fluorescence images of microspots on the PC microfluidic chip at four sets of assayed 
concentrations. Compared with previously reported results obtained by manually 
handling the liquids [19], one visible improvement by using the automatic system is the 
intensity uniformity within spots of the same cytokine. In order to quantitatively 
characterize how easily a spot can be distinguished from background noise, we 
defined SNR as the net signal divided by the standard deviation. A spot with SNR 
larger than 3 is regarded as detectable. Figure 4.5(a) shows that all the cytokine spots 
were detectable over the 1.9 pg/mL-10 ng/mL range. For example, SNRs of the TNF-α 
spots and the IL-3 spots at the lowest concentrations are 49.96 and 78.31, 
respectively. 
The signal intensities from each dilution in the concentration series were used 
to generate standard curves for both TNF-α (Figure 4.5(b)) and IL-3 (Figure 4.5(c)) 
using Prism. The limit of detection (LOD) is defined as the concentration 
corresponding to the blank intensity (i.e. the intensity of the negative control spot of 
PBS buffer) plus 3 standard deviations from all assay spots. Negative controls 
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performed by exposing the capture antibodies to a casein sample resulted in no 
observable fluorescence signal above the background. Therefore LOD values for the 
two cytokines TNF-α and IL-3 are 1.57 pg/mL and 17.96 pg/mL, respectively. While 
the LOD values are similar, the intensity uniformity within the spots is greatly improved 
compared to that obtained without the use of the microfluidic device. Coefficients of 
variance (CVs) were calculated for the IL-3 spots at the lowest four concentrations in 
order to quantitatively compare the intensity uniformity (Table 4.1). It is obvious that 
CVs decreased dramatically by using the microfluidic system for sample handling. For 
example, the CV decreased from 89.82% to 10.54% for the microspots that were 
assayed at the lowest IL3 concentration. 
Table 4.1. Coefficients of variance (CVs) for the IL-3 spots at the lowest four concentrations 
Assay 
concentration 
~2 pg/mL 4 pg/mL 8 pg/mL 16 pg/mL 
CV 
for PC-embeded  
microfluidics chip 
10.54% 4.23% 2.93% 25.96% 
CV 
for a PC chip 
89.82% 22.92% 34.20% 91.64% 
 
4.5 Conclusion 
In this discussion, we designed and fabricated a new platform, the PC 
microfluidic chip, for performing automatic and rapid immunoassays. The PC 
microfluidic chip contains a photonic crystal surface that enhances fluorescence 
signals from the labeling dyes and improves the detection sensitivity. We have 
demonstrated a single-digit pg/mL detection limit for cancer biomarkers (TNF-! and 
IL3) with small intensity variances across the replicate spots by performing a surface-
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based sandwich assay on this PC microfluidic chip. The chip is held in a microfluidic 
system where a computer-controlled pressure adjuster and three-way valve 
automatically perform the immunoassay, and a leak-free fluid interface ensures 
smooth liquid flow. The PC microfluidic platform has ideal features for a practical 
immunoassay: it is automatic and easy-to-use; it can perform multiple assays 
simultaneously; only a small volume of samples and reagents (10 !L) are needed; and 
high analytic sensitivity and high selectivity are achieved without any chemical 
amplifications. Moreover, the use of the automation system greatly reduces spot-to-
spot coefficients of variability compared to manual handling.  
In addition to addressing the current clinical need for improved biomarker 
detection, we believe the PC microfluidic chip developed here has great potential for 
practical immunoassay and point of care diagnostics. Because of the high sensitivity 
and small sample volume, it is possible to perform the assay using a droplet of blood 
from a finger prick, which eliminates the need to visit clinical labs for blood drawing. If 
the microfluidic chip can be integrated with a plasma filter, the blood testing process 
can be further simplified and a patient might be able to perform a test at home. Indeed, 
we are in the process of developing a compact system which combines a photonic 
crystal surface, microfluidic handling, a plasma filter, and a detection instrument. 
Furthermore, we are examining the liquid handling system and incorporating an 
ultrasonic transducer in order to introduce external agitation and reduce the total assay 
time to an hour. 
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4.6 Figures 
 
Figure 4.1. Schematics of the PC microfluidic chip (a) before and (b) after assembling. It was 
assembled using a stack of plastic, Double-Sided Adhesive (DSA) and a nonfluorescent glass 
coverslip. The top layer was 75 mm long, 25 mm wide and 6 mm thick, and contained a 
recessed region (2.2 mm !×!8.2 mm) into which the PC chip of the same dimension was 
attached. The middle layer was made of DSA (3M™ Optically Clear Adhesives 8212) with a ~2 
x 12 mm wide and 150 !m thick channel in the center. The bottom layer was a thin transparent 
coverslip (24 mm x 60 mm x 0.17 mm) through which a camera monitored flow inside the 
channel and a laser excited the fluorophores during the detection. (c) Left: a photo of a 
fabricated microfluidic chip in which red food dye was introduced throughout the inlet; Right: 
SEM of the PC surface. 
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Figure 4.2. (a) Schematics of the microfluidic control system. The 3-to-1 valve introduced 
compressed air, buffer solution or detection antibody labeled with Cy5 into the channel. The 
selection was determined by an automated and programmable microfluidic controller. The fluid 
driving force was supplied by compressed nitrogen which was regulated by a pressure controller 
(Fluigent MFCS-EZ) that provided pulseless and highly stable flows.  A digital camera monitored 
the flow through a hole in the fixture. (b) Schematics of the leak-proof seal. The seal was based 
on force fit between flanged ends of chemically inert tubing and the flat outer surface of the 
microfluidic chip. 
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Figure 4.3. (a) Fluorescent images obtained by scanning a microarray assayed with a 1.9 
pg/mL TNF-alpha sample before (the upper row) and after (the bottom row) removing the glass 
window. (b) Average fluorescent intensities over four replicates with (black bar) and without 
(red bar) glass window. Although the spot intensity obtained with a glass window is higher, the 
net fluorescent intensity is 6.77% lower compared to that without a glass window. 
 
With glass window 
Without glass window 
(a) 
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Figure 4.4. (a) Fluorescent images obtained at (a) on-resonance and (b) off-resonance 
conditions. (c) Reflection spectrum of PC acquired by illuminating the surface over a range of 
incident angles at the fixed excitation wavelength λ = 637 nm. (d) Average fluorescent 
intensities when the PC embedded in microfluidic channel were on resonance (black bar) and 
off resonance (red bar). 
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Figure 4.5. (a) Representative fluorescence images of microspots on the PC microfluidic chip 
at four sets of assayed concentrations. The first row contains TNF-α spots while the second 
row contains IL-3 spots. Standard curves for (b) TNF-α and (c) IL-3. LOD values for two 
cytokines TNF-α and IL-3 are 1.57 pg/mL and 17.96 pg/ml respectively. 
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CHAPTER 5 PCEF FOR HOMOGENEOUS ASSAY USING 
SUBMICRON FLUID CHANNELS FABRICATED BY E-JET 
PATTERNING 
5.1 Chapter Introduction 
In this chapter, we demonstrate the enhancement of a liquid-based 
(homogenous) fluorescence assay using the resonant electric fields from a 
photonic crystal (PC) surface. Because evanescent fields are confined to the 
liquid volume nearest to the photonic crystal, we developed a simple approach 
for integrating a PC fabricated on a silicon substrate within a fluid channel with 
submicron height, using electrohydrodynamic jet (e-jet) printing of a light-curable 
epoxy adhesive to define the fluid channel pattern.  The PC is excited by a 
custom-designed compact instrument that was described previously in Chapter 
2. Using a molecular beacon nucleic acid fluorescence resonant energy transfer 
(FRET) probe for a specific miRNA sequence, we demonstrate an 8x 
enhancement of the fluorescence emission signal, compared to performing the 
same assay without exciting resonance in the PC detecting a miRNA sequence 
at a concentration of 62 nM from a liquid volume of only ~20 nl.  The approach 
may be utilized for any liquid-based fluorescence assay for applications in point-
of-care diagnostics, environmental monitoring, or pathogen detection. 
5.2 Motivation 
We have demonstrated the use of PCEF for surface-based fluorescence 
assay in the previous work.  However, many important classes of fluorescent 
assays are liquid based (homogenerous). For example, Fluorescence Resonant 
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Energy Transfer (FRET) assays and Fluorescence Polarization (FP) assays are 
mainstays for disease diagnostics, pathogen detection, life science research, and 
toxin detection [119-123] that involve conjugation of fluorescent tags to at least 
one liquid-based assay component.  Likewise, chemiluminescence assays and 
polymerase chain reaction (PCR) require detection of photon output from a LED 
or laser-illuminated liquid sample [40, 124, 125].  For each of these applications 
homogeneous assays require the ability to observe weak fluorescent signals 
above background autofluorescence for detection of biomolecular analytes at 
very low concentrations.  
 A fundamental limitation for the application of nanostructured surfaces for 
enhancing the fluorescence of homogeneous assays is that the enhanced 
electric field is tightly confined to the surface, with an evanescent field volume 
that extends only 100-600 nm into the liquid media in contact with the surface 
[48, 55], [19], [53, 126].  In order to achieve a substantial enhancement of the 
fluorescent output from a homogeneous assay using a nanostructured surface, it 
is necessary to confine the liquid volume so that a substantial proportion of it will 
reside within the evanescent field volume.  Therefore, enhancement of the 
fluorescent output of homogeneous assays requires integration of the 
nanostructured surface and a fluid channel with a submicron height dimension.   
A variety of approaches for creating microfluidic channels with submicron 
depth have been demonstrated through the application of photolithography [127, 
128], sacrificial etching [129-132], and PDMS collapse [133-135]. However, these 
techniques either are low throughput, offer poor surface adhesion strength, or 
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poor control of channel dimensions. The electrohydrodynamic jet (e-jet) printing 
approach used here is cost-effective, highly controllable and very simple. E-jet 
printing [136-138] is a nano-manufacturing process that uses electric field-
induced fluid jet printing through micron-scale nozzles to achieve nanometer to 
micrometer-scale droplet placement accuracy and accurate control of ~0.5 pl 
dispense volumes. The printed fluid used in our approach is UV-curable optical 
adhesive (NOA74,!Norland Products Inc., Cranbury, NJ).  Assembly of the flow 
channel requires printing the adhesive pattern upon the PC substrate, attaching a 
glass cover with pre-drilled inlet/outlet holes to the PC surface, and curing by a 
short exposure to UV light. The approach can produce channels of arbitrary 
shape with micrometer-scale precision of lateral dimensions.  
 In this discussion, we demonstrate, to our knowledge, the first reported 
instance of fluorescence enhancement of a homogeneous assay using a 
nanostructured surface.  We utilize a one-dimensional PC slab fabricated upon a 
silicon substrate as the enhancement surface that is designed to resonantly 
couple with a λ = 637 nm laser when the PC is covered in aqueous media.  In 
order to achieve a submicron-height microfluidic channel that can be easily 
integrated with the PC, we demonstrate a new approach for creating a fluid 
channel, in which we print a pattern of droplets of light-curable adhesive using 
electrohydrodynamic jet (e-jet) printing. Rigorous Coupled Wave Analysis 
(RCWA) computer simulations were used to visualize the extent of resonant PC 
evanescent field into the volume of the flow channel, and to predict the electric 
field enhancement experienced by fluorophores extending through the channel 
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volume.  As an exemplary demonstration of homogeneous PCEF, we performed 
a FRET-based molecular beacon assay for detection of a specific miRNA 
sequence. Using a liquid volume of 20 nL to fill the nanochannel, we 
demonstrated up to 8 x increase in fluorescence intensity by exciting the PC 
under resonant coupling conditions and detected the miRNA at a concentration 
as low as 62 nM. 
5.3 Methods 
5.3.1 Device Structure and Detection Principle  
The sensor structure is comprised of a transparent glass layer, the 
microfluidic channel region, and a PC surface for fluorescence enhancement 
(Figure 5.1a). As liquid flows through the channel, the fluorescent emitters will be 
excited by the laser illumination, with fluorophores closest to the PC surface 
experiencing electric fields that are amplified with respect to the incident laser 
intensity. Fluorescent emission is detected through the transparent glass cover.  
The structure and fabrication of PC was described previously in Chapter 2. 
Resonant modes of the PC can be excited at a specific incident angle for a given 
laser illumination wavelength [53]. At the resonance coupling condition of the PC, 
the enhanced electric fields are confined to the surface of the device, and extend 
into the adjacent media with exponentially decaying intensity as one moves away 
from the PC surface. By confining the assay solution to the evanescent field 
region of the PC, one can achieve an increase in the emission intensity of the 
dye throughout the channel.  
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A commercially available simulation tool for RCWA (DIFFRACTMOD, 
RSoft) was used to characterize the device response to an incident transverse 
magnetic (TM) illumination source at λ = 637 nm. In the model, refractive indices 
were assigned using previously measured values for each material (nTiO2 = 2.35, 
nSiO2 = 1.46, nGlass= 1.52, nWater = 1.33) and device dimensions were used as 
specified in our previous description. The upper surface of the microfluidic 
channel was placed at a height of t = 830 nm, using values obtained from 
fabricated devices (Figure 5.2f).  
We first calculated combinations of incident angle and wavelength that 
result in resonant coupling to the PC, at which electric field enhancement occurs 
[139]. Simulation predicts that, for a laser source of λ = 637nm, the reflectance is 
maximized for an incident angle of θ = 1.55 degrees with respect to normal. By 
Snell’s Law, the corresponding resonant angle for illuminating the upper surface 
of the glass window, which should be used to compare with the experimental 
results, is θair = 2.39 degrees. Simulation of the local electric field distribution at 
the resonant condition (Figure 5.1c), predicts that the maximum electric field 
enhancement is 225 x the incident electric field magnitude of the laser, and 
shows that the greatest field enhancements occur within the TiO2 film and in the 
regions in direct contact with the TiO2. The simulations show that the field 
enhancement decays rapidly with increasing distance, d, from the PC, and that 
some regions on the PC surface experience greater electric field magnitude than 
others. To quantify the field enhancement as a function of d, taking into account 
the electric field distribution, we define the average enhancement factor !!"#$!%# 
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as the average intensity (|E|2) enhancement of all the points in the simulation with 
a distance d from the PC surface. Mathematically, the averaged enhancement 
factor is defined as , where !!"#$! !,!  is the 
electric field enhancement at location (!,!).  is plotted with d ranging 
from 5 nm to 700 nm (Figure 5.1d), showing that the field enhancement 
decreases rapidly as one extends the liquid volume further from the PC surface. 
The zoom-in plot (inset of Figure 5.1d) suggests that no significant enhancement 
of the local intensity is observed when a fluorescent molecule is placed at a 
distance of ~500 nm from the PC surface, implying that the fluorescent molecules 
should be confined within the 500 nm volume above the PC in order to obtain a 
substantially enhanced fluorescence signal. 
5.3.2 E-Jet Printing of the Submicron-Channel 
A novel fabrication method based upon e-jet printing was developed to 
create the submicron channels. Micron-size droplets of NOA74 were printed 
upon the PC substrate to form a channel pattern.  Separately, a glass cover was 
prepared by drilling two inlets holes and one outlet hole.  The glass cover and the 
epoxy-patterned PC were subsequently aligned and bonded by squeezing them 
together, followed by curing the adhesive by exposure to UV illumination.  
The e-jet printing approach uses an electric field to induce droplet release 
flow from a micro capillary nozzle to the substrate, eliminating the need of a 
mask, while allowing precise printing of any desired pattern [137]. The 
microfluidic channel is 500 µm wide and 13.6 mm long, with a central detection 
2
0
( ) ( , ) /average localF d E x d dx
Λ
= Λ∫
( )averageF d
! 90!
region with a diameter of 2 mm. The assay region width was selected to fit the 
extent of the focused laser illumination line provided by the detection instrument. 
The channel lateral dimensions were defined by filling the regions surrounding 
the channel with printed droplets of adhesive, as shown in Figure 5.2a. In order 
to achieve a channel thickness as small as possible, NOA74 was chosen as the 
optical adhesive due to its low viscosity (80-95 cps) at room temperature. The 
droplet size and droplet density were selected to achieve a continuous adhesive 
film after the PC-glass attachment step, while avoiding the use of excessive 
material that would result in lateral flow, which would reduce the channel width. 
We used a gold/palladium (Au/Pd) coated nozzle with a tip diameter of 5 µm that 
was placed 30 µm from the continuously moving PC surface (v = 1 mm/s). The 
NOA74 was extracted [138] from the nozzle to the PC substrate to form discrete 
droplets, under a periodically modulated voltage (280 V high and 220 V low, 20 
Hz) at room temperature and 30% humidity. The printing process required ~20 
minutes to produce the pattern for one microfluidic channel. Each droplet 
occupies an area of ~20 X 30 µm2, with 10 - 30 µm spacing between droplets 
(Figure 5.2d). The vertical height of the droplets before being squeezed was 
measured to be 1.2 ± 0.1 µm using a stylus contact profilometer (Alpha-Step IQ,!
KLA-Tencor Inc., CA), and the squeezing process is intended to reduce the 
adhesive height as the droplets spread to fill their surrounding volume.   
To complete device fabrication, a glass cover was prepared with three 
holes (diameter = 1mm) to match the inlets/outlet locations of the channel. An 
evenly distributed force of ~100N was applied at room temperature by a 20 lb 
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Teflon-wrapped steel handheld roller. An optical image of the NOA74 after 
attachment to the glass cover is shown in Figure 5.2e, demonstrating that the 
droplets spread out and overlap with each other after squeezing. Finally, the 
adhesive was cured by exposing the assembly through the glass cover to a high 
intensity UV lamp (Xenon) for 50 seconds. Plastic tubing with inner diameter of 
0.75 mm and outer diameter of 1 mm were inserted into the inlets and outlet and 
sealed with optical adhesive (NOA62, Norland Products Inc., Cranbury, NJ ) that 
was cured by a second exposure to the UV lamp.  
A completed microfluidic assembly and a magnified view of the 
observation window are shown in Figure 5.2b-c. The two inlets are provided to 
enable separate introduction of the test sample and the assay label reagent, 
where they are allowed to mix within the central flow channel and assay region.  
For this work, measurements are performed while no flow occurs within the 
device. Between assays, buffer is introduced through both inlets, and waste is 
collected through the outlet port. Visual observation shows that smooth channel 
walls are obtained after droplet inter-diffusion along the straight sections of the 
microfluidic channel, but that the channel edges are irregular surrounding the 
rounded detection region.  Because the PC grating lines are oriented parallel to 
the microfluidic channel, we hypothesize that the compressed adhesive is able to 
preferentially flow along the low portions of the grating, and is less able to flow in 
the direction perpendicular to the grating. Cross section SEM images of the 
channel (Figure 5.2f) were used to measure a fluid channel height of 830 nm.   
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5.4 Results 
5.4.1 Fluorescence Enhancement Characterization 
Using the custom reflection setup mentioned in Chapter 1, we measured 
the resonant angle of PC in water is 2.4 degree, which matches the simulation 
prediction. The fluorescence intensity enhancement provided by the PC can be 
determined by comparing the fluorescent emission intensities from a channel 
with the PC surface illuminated at the resonant coupling condition (on-resonance) 
to measurement from the same channel when the PC is illuminated at an angle 
that does not satisfy the resonant coupling condition (off-resonance). The 
enhancement factor (EF) is defined as 
, 
where , , and represent the fluorescence from a bulk dye 
solution and background fluorescence from buffer when the illumination of PC is 
on-resonance and off-resonance respectively. The EF was initially characterized 
by filling the fluid channel with a fluorescent dye (LD700, Exciton Inc., Dayton, 
OH, USA) dissolved in water at a concentration of 540 ng/ml, and measuring the 
fluorescent intensity , and  via illumination on-resonance (θ = 2.4 
degrees) or off-resonance (θ = 0.1 degrees). The background fluorescence 
intensities  and  were determined by detecting the fluorescence from 
the device filled with DI water. The fluorescence intensity for each measurement 
is the sum of the fluorescence from the center of the illuminated area of 8 µm X 
1mm. All of the fluorescence intensities were detected under the same 
_ _ _ _( ) / ( )fluo on bg on fluo off bg offEF I I I I= − −
_fluo onI _bg onI _fluo offI _bg offI
_fluo onI _fluo offI
_bg onI _bg offI
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instrument settings (laser current = 70 mA, and CCD gain = 1, sensitivity = 0, 
exposure time = 0.04 ms).  
 As shown in the angle spectrum (Figure 5.3), the on-resonance 
fluorescence signal is = 207584 counts while the off-resonance 
fluorescence signal is = 39472 counts. The background fluorescence were 
measured as = 57840 counts and = 21200 counts for the respective 
off-resonance and on-resonance conditions. An enhancement factor of 8.2 can 
be calculated by applying the EF definition, representing the gain supplied by the 
enhanced excitation effect, indicating the potential to achieve an order of 
magnitude increase in fluorescence signal, compared to performing the same 
assay without a PC.   
5.4.2 Bio-Detection Demonstration by Molecular Beacon Assay  
A homogeneous fluorescent assay using molecular beacon probes for 
detection of a specific miRNA sequence was performed by flowing solutions 
containing the molecular beacon probe and a sample containing the target 
miRNA simultaneously through the two inlets. We utilized a previously reported 
molecular beacon probe and miRNA pair as an initial demonstration of PC 
enhanced fluorescence of a homogenous assay [140]. The molecule miR-21(5’-
ACTCC TACG GGACGCAGC-3’) was the target while a mutant molecule miR-21 
with a single base mismatch (5’-ACTCC TACG CGACGCAGC-3’, mismatched 
base is marked in bold) was used as a negative control for demonstration of 
selectivity. Both of the mutant miR-21 and the mature miR-21 were diluted by 
_fluo onI
_fluo offI
_bg onI _bg offI
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phosphate buffer sodium (PBS, pH = 7.4) into five concentrations ranging from 
62 nM to 1 µM. The molecular beacon was designed to be complementary to the 
mature sequence of miR-21 (Cy5-5’-CATCC GCTGC CTCC CGTA GGAG T G-
3’-BHQ2, the complementary region is indicated in bold). Each beacon consists 
of a 5’ Cy5 fluorophore, a 3’ BHQ2 quencher and a hairpin stem-loop sequence 
that is complementary to the mature miRNA flanked by residues necessary to 
form a beacon stem. The beacon solution was diluted to a concentration of 1 µM. 
The mature miR-21, mutant mature miR-21, and DNA molecular beacons were 
synthesized by Integrated DNA Technologies!(Coralville, Iowa).  
The performance of sensor and detection instrument were studied in the 
context of a molecular beacon assay for miR21. A 1 µM DNA molecule beacon 
solution and test sample containing mature miR21 were pumped into two 
separate inlets by a syringe pump (PHD2000 series, Harvard Apparatus) at a 
pumping rate of 0.5 µL/min for ~5 minutes. Waste liquid was collected at the 
outlet. The total volume inside the channel was calculated to be ~20 nL. After 
performing a fluorescence intensity measurement and flushing the system 
completely with deionized water, the detection experiment was repeated, using a 
new miR21 concentration. The concentrations of miR21 were 31 nM, 62 nM, 125 
nM, 250 nM, 500 nM after dilution with the molecular beacon. Based upon 
previous studies of intermixing between laminar flows adjacent introduced into 
the same flow channel, we expect complete intermixing between the two 
reagents to occur through the 10 mm channel length, resulting in a mixed sample 
reaching the circular measurement zone. Fluorescence intensities from the 
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center of the observation window were collected over a range of incident angles 
for each concentration. The donor fluorophore of molecular beacon probe is not 
completely quenched when the probe is in its native unreacted state, resulting in 
the presence of “background” fluorescence, even if no target is present.  The 
background fluorescence is also amplified by PCEF, thus we expect to observe 
higher fluorescence intensity even for zero concentration of the analyte.  We 
define the noise of the fluorescence measurement to be the standard deviation of 
the fluorescent intensity when no target molecule is present, in which the 
standard deviation is obtained by measuring the same zero concentration sample 
three times in a row.  The lowest detectable fluorescence intensity is defined as 
the mean of these three measurements, plus 3 x the standard deviation.  The 
background fluorescence level was measured by this approach for the case 
when the PC is illuminated in the on-resonance state, and again with the PC 
illuminated at the off-resonant state.  The off-resonance illumination is obtained 
by de-tuning the illumination angle by 2 degrees from the on-resonant angleIn 
order to demonstrate the selectivity of the assay, a concentration series of 
mutant mature miR21 (62 nM, 125 nM, 250 nM, 500 nM, 1 uM) were added into 
the 100 µL beacon solution as controls. The fluorescence intensities were 
obtained with the PC illuminated on-resonance and off-resonance for each 
concentration, and compared with that from the mature miR21. Hybridization of 
beacon to miRNA was performed for 3 min, as verified by performing the assay 
in a conventional 100 µL cuvette, and measuring the output with a conventional 
fluorometer (Varian Cary Eclipse fluorometer, Agilent). Detection instrument 
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settings for measuring fluorescence output from the PC-integrated flow channel 
were the same for all measurements. (laser current = 80 mA, CCD camera 
sensitivity = 70, gain = 1 and integration time = 0.04 ms).   
Dose-response curves for detection of mature miR21 (target, black lines) 
and mismatched mutant miR21 (control, blue lines), obtained from the device 
illuminated using on-resonance (solid lines) and off-resonance (dashed lines) 
conditions are plotted together in Figure 5.4(a). The comparison between 
fluorescence intensities at the same concentration both on-resonance and off-
resonance clearly shows that much stronger fluorescence were produced by the 
PC surface. The enhancement was calculated to be ~8x for the miRNA mixture 
with concentrations higher than 62 nM. The figure also demonstrated the 
selectivity of the assay. As shown in Figure 5.4(a), the fluorescence from the 
mutant mature miR21 with the highest concentration (500 nM) is only 1/7 of that 
from the mature miR21 at the on-resonance condition and no fluorescence was 
detectable in samples with concentration lower than 250 nM, demonstrating 
excellent selectivity. 
To determine the detection limit, the fluorescent intensities of the 
hybridized target and the background are plotted together in Figure 3.4b.  The 
solid black represents the on-resonance fluorescence intensities of the 
hybridized targets at different concentrations. The error bars represent the 
standard deviation of three separate fluorescence measurements for each 
concentration. The on-resonance lowest detectable fluorescence signal Ml = 
77200 (the solid red line in Figure 3.4b), which was calculated by adding the 
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background fluorescence Mb = 74800 and the noise Sd = 800, is slightly higher 
than the fluorescence from the 31 nM hybridized target. Therefore the detection 
limit for on-resonance PC is 62 nM. The result demonstrates the high sensitivity 
of the biosensor, considering only ~0.02 µL sample solution was used to fill the 
channel, representing ~7.4 X 106 molecular beacon probes for the assay. By 
comparing the fluorescence from the samples (dashed black line) and the lowest 
detectable fluorescence (dashed red line), the detection limit of the off-resonance 
PC is 125 nM.  Although the background fluorescence was slightly enhanced, the 
sensitivity was still substantially improved utilizing the PC resonance effect.  
5.5 Discussion and Conclusion 
We have demonstrated an 8x fluorescence intensity increase for detection 
of miRNA in a homogeneous molecular beacon assay by a PC as one of the 
internal surfaces of a microfluidic channel.  The increased sensitivity enables 
detection of 62 nM miRNA in a 20 nL sample.  In order to confine the liquid 
volume within the evanescent field region of the PC, we developed an e-jet 
printing method to inexpensively fabricate fluid channels with <1 µm channel 
height that utilizes the PC as one internal surface. 
The approached demonstrated here may be applied to any homogeneous 
fluorescent assay, including FRET, that is typically performed in a cuvette and 
measured by a conventional fluorometer, with the benefit of consuming a ~3-
orders of magnitude lower sample volume. Another fluorescent assay that may 
potentially benefit from this approach is polymerase chain reaction (PCR), which 
requires several thermal cylces to create enough fluorescently tagged products 
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to generate a measurable signal from sample volumes in excess of 20 µL. The 
enhanced fluorescence provided by a PC integrated within a fluid channel may 
enable detection of PCR products with fewer cycles of amplification and thus a 
shorter detection time.  
An important aspect of this research is that the fluorescence enhancement 
was achieved in a microfluidic format that permits the integration of functional 
components and allows high throughput detection. By multiplexing the operation 
of several parallel microfluidic chambers, the presence of multiple miRNA 
sequences may be probed at the same time.  
To conclude, we have presented a novel method, supported by 
experimental demonstrations and numerical modeling, to enhance the 
fluorescence of a homogeneous molecular beacon assay, in which the analyte 
solution is confined to the evanescent field region of a PC surface by a 
submicron-height microfluidic channel. A simple and inexpensive fabrication 
technique based on e-jet printing was developed to create the shallow channel. 
The approach yields excellent sensitivity while consuming only nL reagent 
volumes per assay. In light of the simplicity of the detection instrument and the 
compatibility with existing biodetection tools, this approach may be broadly 
applied in disease diagnostics and other fluorescence-based sensing 
applications. 
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5.6 Figures 
 
Figure 5.1. (a) Schematic diagram of the device structure, comprised of a transparent 
glass layer, a microfluidic region and a PC surface for fluorescence enhancement. (b) 
SEM image of the one-dimensional PC with a period of 360 nm and duty cycle of 36%. 
(c) Evanescent electric field enhancement distribution at the resonant coupling condition 
of the PC. (d) The average enhancement of field intensity as the function of distance, d, 
above the top TiOa2 layer of the PC. 
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Figure 5.2.  (a) Schematic diagram of the fabrication process: I. The channel pattern 
was e-jet printed on a silicon PC (Si-PC); II. The Si-PC was carefully aligned with a glass 
slide and pressed against each other by a roller to squeeze the droplets. The layout of 
the channel consisting of two inlets with diameters DI = 1 mm (left), one observation 
window with a diameter DR = 2 mm (middle), and one outlet with a diameter DI = 1 mm 
(right). The total length and the width of the channel are L = 13.6 mm and W = 0.5 mm. 
(b) Photograph of the PC integrated into the submicron flow channel. (c) Optical image 
of the observation window. (d) Optical image of the printed NOA74 droplets. (e) Optical 
image of the continuous NOA74 film after squeezing the droplets. (f) SEM image of 
cross section of a completed device, showing the thickness of the channel is ~830 nm.  
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Figure 5.3. Fluorescence intensities obtained from 50 µg/mL LD700 solution filled within 
the channel when excited over a range of illumination angles. 
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Figure 5.4. Results of the miR21 detection by DNA molecular beacon assay.  (a) Dose 
response curves of mature miR21 (target, black lines) and one pair mismatched mutant 
miR21 (control, blue lines), obtained from PC at on-resonance (solid lines) and off-
resonance (dashed lines) conditions. The results confirm the selectivity of the assay as 
well as the PCEF enhanced excitation effect. (b) A zoom-in plot of the fluorescence 
intensities for the detection of mature miR21 at on-resonance (black, solid line) and off-
resonance (black, dashed line) conditions. The red lines represent the lowest detectable 
fluorescence at on-resonance (solid line) and off-resonance (dashed line) conditions. 
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CHAPTER 6 CONCLUDING REMARKS 
6.1 Summary of Current Work 
This dissertation makes a number of contributions to advancing the 
PCEF technology. It expands the application of PCEF to allergy test, allows 
automatic assay by integrating microfluidic channels, and implements the PCEF 
technology to another important fluorescence assay –molecular beacon assay. 
The following is a summary of the main contributions. 
1. Detection of low-concentration allergen-specific Immunoglobulin E 
(IgE) in human sera using a Photonic Crystal Enhanced Fluorescence (PCEF) 
microarray platform. A comparison of the lowest detectable concentration of IgE 
measured by the PC microarray system and a commercially available clinical 
analyzer demonstrated that the PCEF microarray system provides higher 
sensitivity. The PCEF system was able to detect low concentrations of specific 
IgE ~0.02 kU/L, which is 5-fold to 17-fold more sensitive than the commercially 
available FDA-approved analyzers. In preliminary experiments using multi-
allergen arrays, we demonstrate selective simultaneous detection of IgE 
antibodies to multiple allergens. 
2. Development of a detection platform that integrates photonic crystal 
surface with a microfluidic cartridge. Simultaneous goals of high analytic 
sensitivity (single-digit pg/mL), high selectivity, low sample volume, and assay 
automation were achieved. A plastic microfluidic device for holding the PC was 
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created using a low-cost and flexible process. An assay automation system that 
utilizes a leak-free fluid interface was built to introduce the correct sequence of 
fluids through the microfluidic device. Through the use of the assay automation 
system and the PC embedded within the microfluidic device, 1.59 pg/mL-level 
limit of detection was demonstrated by performing a representative biomarker 
assay (for IL3 and TNF-α). Improved intensity uniformity from spot-to-spot was 
achieved by the microfluidic automatic system compared to performing assays 
with manual manipulation of assay liquids. The system’s capabilities, when fully 
developed, are compatible with the goal of diagnostic instruments for point-of-
care settings. 
3. Enhancement of a liquid-based homogenous fluorescence assay 
using the resonant electric fields from a PC surface. A PC was integrated within 
a fluid channel with submicron height, using electrohydrodynamic jet (e-jet) 
printing of a light-curable epoxy adhesive to define the fluid channel pattern. 
Using a molecular beacon nucleic acid fluorescence resonant energy transfer 
(FRET) probe for a specific miRNA sequence, an 8x enhancement of the 
fluorescence emission signal was demonstrated, compared to performing the 
same assay without exciting resonance in the PC detecting a miRNA sequence 
at a concentration of 62 nM from a liquid volume of only ~20 nl.  The approach 
may be utilized for any liquid-based fluorescence assay for applications in point-
of-care diagnostics, environmental monitoring, or pathogen detection. 
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6.2 Future Work 
While we have successfully demonstrated high sensitivity, multiplexed and 
automatic platform for biomarker detection by integrating PC surface and 
microfluidic channels, there are still needs to further improve the platform so that 
the system can be readily used in clinical environment. Our future direction will 
require integrating several innovations into the current platform: (1) The Si-PC 
integrated with Fabry-Perot optical cavity will be used to deliver ~50x greater 
signal enhancement than current-generation PCEF devices. (2) A laser-
machined blood filter will separate plasma from a droplet of heparinized whole 
blood in 60 seconds. (3) Use of ultrasonic agitation to speed the immunoassay, 
enabling the entire assay protocol to be performed automatically in <60 minutes 
without user intervention.  
In order to improve the sensor’s performance, we will incorporate the Si-
PC with a Fabry-Perot cavity [141]. The function of the mirror is two-fold.  First, 
it will reflect fluorescence emission of the PC surface that would normally be 
directed downward (away from the detection optics), increasing detected 
photon intensity by 2x.  Second, computer models suggest that it is possible to 
choose the distance between the PC surface and the mirror so as to establish a 
Fabry-Perot optical cavity, in which constructive interference results in 3-5x 
greater electric field intensity at the plane of the assay surface. We will fabricate 
the PC using a silicon substrate, with the PC grating structure defined by deep-
UV photolithography and reactive ion etching in a semiconductor foundry.  This 
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approach provides uniform and low-cost fabrication of the PC grating together 
with a metal reflection mirror beneath the PC.   
In a clinical laboratory setting, plasma separation from whole blood can 
easily be performed using centrifugation, although collection of blood and its 
processing remain challenging at the point of care (POC) [142-144]. Inclusion of 
blood cells or their components in an ELISA results in inaccurate quantification, 
reduced sensitivity, or even assay failure [145, 146]. Therefore, on-chip plasma 
separation from blood cells is required to obtain optimal assay performance. In 
our future work, we will focus on developing an approach to easily integrate a 
plastic filter with the microfluidic cartridge. Although a variety of microfluidic 
approaches for achieving on-chip plasma separation have been reported 
utilizing capillary force [147], the Zweifach-Fung effect [148] and H2O2-powered 
pumping [149], there is still an unmet need for a simple and rapid plasma 
separation device to facilitate point-of-care testing for ELISA applications [150]. 
We will collaborate with the Demirci Group at Stanford to integrate the plasma 
filter with the microfluidic chip. The Demirci Group recently demonstrated a 
microchip that can separate plasma and virus selectively from unprocessed 
whole blood by using an elegant approach that does not require an external 
pump or substantial dilution of the sample. As described in preliminary results, 
the approach was originally developed for separation of virus from whole blood, 
where up to 89.9 ± 5.0% HIV virus was recovered in the flow-through while 81.7 
± 6.7% of RBCs and 89.5 ± 2.4%of WBCs were retained by the filter. The 
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approach utilizes an inexpensive laser-cut polymer membrane filter that can be 
easily integrated with the microfluidic cartridge. 
Acoustic streaming is an effective mixing technique applicable to 
microarrays. In this technique, an ultrasound wave passes through a liquid 
medium (coupling gel) and transfers the momentum to the test fluid, generating a 
steady circular flow occurring in a high-intensity non-linear acoustic field. 
Therefore, the target molecules in the sample were observed to move in both 
vertical and horizontal directions under the influence of acoustic streaming 
facilitating hybridization with capture molecules on the surface [151-153]. In the 
previous study, fluorescence signal from DNA hybridization was increased by 
24% using acoustic streaming with applied voltage of 24 V and resonant 
frequency of 1.67 MHz [152]. In our future work, we will use a piezoelectric 
ultrasonic transducer (resonant frequency = 1 MHz, Olympus NDT Inc., MA, 
USA) to create the acoustic streaming during the sample incubation step. The 
transducer will be driven by a square wave (Vpp = 10 V) generated by a function 
generator (model 33210A, Agilent Technologies, CA, USA) at the applied voltage 
of 10 V. To avoid the heat accumulated, the transducer will be turned on and off. 
The on and off times for activating the disks will be varied to find an optimum 
condition. To minimize the reflected power, a layer of coupling gel will be used to 
effectively couple the acoustic wave into the sample. 
Significant funds and efforts have been committed to the future of cancer 
diagnostics with the hope of solving several existing formidable analytical 
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challenges; if successful, the payoff and utility of such a detection platform will be 
great. 
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